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ABSTRACT
The aim of this study was primarily to establish the 
time course effects of chronic cold exposure and associated 
cold acclimation on glucagon (and insulin) secretion from the 
pancreatic islets of Langerhans in the rat, and to elucidate
the possible adrenergic mechanisms involved in the regulation
of glucagon secretion in the cold acclimated animal. The 
data were obtained by monitoring changes in basal and 
arginine stimulated glucagon (and insulin) secretion from the 
isolated perfused rat pancreas using a purpose built 
perfusion system.
The study confirmed that glucagon secretion from the 
isolated perfused pancreas in response to
arginine-stimulation, follows a biphasic pattern. The data 
indicated that chronic cold exposure results in an 
enhancement of glucagon secretion during the initial four 
weeks of cold exposure followed by a return to control levels 
after six weeks of exposure. Associated measurements of 
insulin secretion demonstrated a progressive reduction in 
insulin secretion, and insulin:glucagon molar ratios showed a 
sustained reduction throughout the cold exposure period
studied. It was suggested that the enhanced glucagon and 
decreased insulin response might be the result of a cold
induced increase in sympathetic activity. The disappearance 
of the enhanced glucagon response after six weeks cold 
exposure was postulated to be the result of desensitisation 
of the pancreatic A cell to sympathetic stimulation. Studies 
using alpha and beta adrenergic antagonists supported this 
hypothesis, with indications of a removal, after 6 weeks cold
exposure, of the inhibitory influence of beta blockade seen 
in the warm acclimated animal. The studies also indicated an 
inhibitory effect of alpha blockade after cold acclimation, 
suggesting that alpha adrenoreceptor stimulation of the A 
cell may be involved in the regulation of glucagon secretion 
in the cold acclimated animal.
Paradoxically, dose-response studies perfusing the 
isolated rat pancreas with exogenous noradrenaline were 
unable to demonstrate a reduced sensitivity of the A cell to 
noradrenaline, indeed there was some evidence to suggest an 
increased sensitivity to noradrenaline in the cold acclimated 
animal, although it is suggested that • differential vascular 
effects of noradrenaline in the pancreas of the cold 
acclimatad animal may contribute to this paradoxical 
response.
It is concluded that during the process of cold 
acclimation, the initially enhanced glucagon secretion could 
contribute to the maintenance of an adequate supply of 
thermogenic substrates, this response disappearing with 
continued cold exposure, possibly as the result of changes in 
islet adrenergic sensitivity. The continued reduction in 
insulin secretion, resulting in maintained low
insulin:glucagon molar ratios, could result in an enhanced 
tissue sensitivity to the glucogenic and lipolytic actions of 
glucagon, thus possibly enhancing the processes of glucagon 
induced substrate mobilisation in the cold acclimated animal.
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1 INTRODUCTION
1.1 Preamble
The objectives of the present investigation were to 
establish the time course effects of chronic cold exposure, 
resulting in cold acclimation, on basal and arginine 
stimulated glucagon (and insulin) secretion from the isolated 
perfused pancreas, and to evaluate the possible role of 
adrenergic mechanisms in regulating glucagon secretion.
This introduction will therefore consider the 
physiological response to both acute and chronic cold 
exposure, where a fall in environmental temperature below the 
thermoneutral zone causes the stimulation of thermogenic 
mechanisms which are the result of specific cold-stimulated 
metabolic and cardiovascular responses. Cold exposure has 
been shown to stimulate the sympathetic nervous system, thus 
the primary role of catecholamines in regulating the 
metabolic and cardiovascular responses to both acute and 
chronic cold exposure will be discussed. Finally, in view of 
the role for glucagon in the mobilisation and distribution of 
energy substrates, the contribution of glucagon to the 
regulation of the metabolic response to a cold stimulus will 
be considered, as will the regulatory mechanisms that might 
serve to modulate pancreatic A cell secretion in response to 
cold, particularly the stimulatory effects of the sympathetic 
nervous system.
1.2 The Physiological Response to Cold
1.2.1 Acute Cold Exposure
Acute cold exposure has been considered as exposure to 
a low environmental temperature (0 - 10 °C) for periods of
time ranging from 90 min to 7 days (Seitz, Krone, Wilke and
Tarnowski 1981; Picotti, Carruba, Ravazzani, Cesura, Galva 
and Da Prada 1981; Foster and Frydman 1979; Takahashi, 
Murata and Matsumoto 1984; Sasaki, Takahashi, Aso, Ohneda 
and Weekes 1982). For the purposes of this study acute cold
exposure will be defined as exposure to 4 °C for a maximum
period of 7 days.
During acute cold exposure body temperature is 
maintained primarily by shivering therrnogenesis within 
skeletal muscle (Himms-Hagen 1972). This increased heat 
production is facilitated by specific metabolic and 
cardiovascular changes within the animal:
I) Mobilisation of substrates - In order to meet the 
increased energy demands of cold-stimulated thermogenic 
processes there is a significant increase in mobilisation and 
utilisation of specific substrates. Thus free fatty acids 
are mobilised from both white and brown fat depots (Portet, 
Laury, Bertin, Senault, Hluzko and Chevillard 1974; 
Himms-Hagen 1972; Minaire, Vincent-Falquet, Pernod and 
Chatonnet 1973) to provide substrates for the increased
metabolic activity. Similarly carbohydrate turnover is 
increased (Depocas 1959; Depocas 1962; Minaire et al 1973 ) 
due to an increased glycolysis and gluconeogenesis 
(Cunningham 1985). Evidence of stimulated carbohydrate 
turnover also includes diminished glycogen stores and 
increased carbohydrate utilisation (Depocas 1959).
II) Cardiovascular changes - In order to meet the 
increased oxygen demand resulting from these thermogenic 
processes and also to minimise heat loss, acute cold exposure 
results in specific cardiovascular responses. Studies by 
Foster and Frydman (1979) and Jansky and Hart (1968) 
demonstrated increases in cardiac output and heart rate in 
response to acute cold exposure. They also showed 
differential readjustments of organ blood flow, with 
increased fractional distribution of cardiac output to 
respiratory organs such as the rib cage and diaphragm, to the 
heart and also to non-respiratory skeletal muscle. Decreased 
cutaneous blood flow was also seen.
1.2.2 Cold Acclimation
The term cold acclimation has been used to describe 
adaptive events occurring in animals chronically exposed to a 
low environmental temperature (0 - 10°C) for periods of time 
ranging from 3 to 6 weeks (Kuroshima and Doi 1976; Foster 
and Frydman 1978; Portet et al 1974). However the trophic 
response of brown adipose tissue (BAT) (Senault, Cherqui, 
Cadot and Portet 1981; Desautels, Zaror-Behrens and
Himms-Hagen 1978; Thomson, Haebeck, Nance and Beetham 1969), 
used as an indicator of acclimatory status (Bukowiecki, 
Collet, Follea, Guay and Jahjah 1982), suggest that cold 
acclimation occurs within a period of 3 weeks. Thus, for the 
purpose of this study, cold acclimation will be defined as 
chronic exposure to an environmental temperature of 4 °C for a 
minimum period of 3 weeks.
Cold acclimation results in several adaptive changes 
in the aforementioned responses to acute cold exposure 
culminating in the development of non-shivering thermogenesis 
(NST) as the sole mechanism of heat production (Himms-Hagen 
1972, 1976, 1984, 1985; Jansky 1973; Gale 1973). This is
largely due to a "loose-coupling’1 of oxidative phophorylation 
in BAT resulting in increased heat dissipation (Nicholls 
1983). This is believed to be the result of a unique energy 
dissipating mechanism within the BAT mitochondria which are 
shown to posses a high effective proton conductance across 
the inner mitochondrial membrane (for review of biochemical 
mechanisms see Nicholls and Locke 1984). The activity of the 
proton conductance pathway is related to the presence of a 
specific mitochondrial protein with a molecular mass of 
32,000 (32K protein), (Locke, Rial and Nicholls 1982;
Nicholls 1979) the activity of which is modulated by 
nucleotides and free fatty acids (Locke et al 1982a,b; 
Bukowiecki, Follea, Lupien and Paradis 1981). Indeed there 
is evidence to suggest that the presence of the 32K protein 
confers an enhanced sensitivity to the uncoupling effects of 
free fatty acids (Nicholls 1983). Thus free fatty acids are 
both modulators of NST and energy substrates for NST. The 
development of non-shivering thermogenesis is the result of
several adaptive responses to chronic cold exposure:
I) The trophic response of BAT - This response 
consists of a several fold increase in BAT weight (Bukowiecki 
et al 1982; Thomson et al 1969; Desautels et al 1978; 
Senault et al 1981) due to both hyperplasia and hypertrophy 
(Senault et al 1981) and is characterised by an increase in 
total tissue DNA amd protein content (Bukowiecki et al 1982). 
Accompanying these responses are several changes involved 
with mitochondrial development. Thus there is an increase in 
mitochondriogenesis, mitochondrial protein and respiratory 
enzyme activity (Trayhurn, Richard, Jennings and Ashwell
1983). Finally there is a selective increase in the 
proportion of the specific 32k dalton protein in the 
mitochondrial membrane (Desautels et al 1978; Trayhurn et al 
1983; Lean, Branch, James, Jennings and Ashwell 1983), which 
is reflected by an increase in mitochondrial GDP-binding 
(Desautels et al 1978; Trayhurn et al 1983). Bukowiecki £t 
al (1982) have suggested that the trophic BAT response to 
chronic cold exposure was primarily responsible for the 
increased capacity of the cold acclimated animal to generate 
heat by NST.
II) BAT and the mobilisation of energy substrates - In 
the cold acclimated animal there is an adaptive change in the 
role of BAT in lipid metabolism (Himms-Hagen 1972). In warm 
acclimated animals BAT functions as a lipid reserve, whilst 
in the cold acclimated animal it becomes a tissue of heat 
production. Thus release of fatty acids produced by 
lipolysis within the tissue is reduced, and the retained free 
fatty acids serve as substrate for the process of
non-shivering thermogenesis within the tissue. This was 
elegantly demonstrated by Portet et al (1974) who showed that 
stimulation with noradrenaline caused an increase in BAT 
venous free fatty acid levels in warm acclimated animals 
whilst in cold acclimated animals a significant decrease in 
BAT venous free fatty acid levels was seen, despite 
indications from BAT venous blood glycerol concentrations 
that the rate of lipolysis was unaltered.
In support of this redistribution of free fatty acid 
utilisation, adaptive changes in the activity of the enzyme 
lipoprotein lipase are seen. This enzyme is responsible for 
the uptake of triglycerides from the very low density 
fraction of lipoproteins in the blood (VLDL). Thus a 
decrease in white adipose tissue lipoprotein lipase activity 
is observed during cold acclimation (Himms-Hagen 1972) with a 
concomittant increase in BAT lipoprotein lipase (Carneheim, 
Nedergaard and Cannon 1984; Goubern and Portet 1981), 
suggesting that triglyceride is directed towards different 
sites of utilisation in the cold acclimated animal.
Ill) Cardiovascular effects - Increases in heart rate 
and cardiac output in response to cold are significantly 
enhanced in the cold acclimated animal (Foster and Frydman 
1979; Jansky 1968). Changes in tissue blood flow and 
fractional distribution of cardiac output in response to cold 
are also different in the cold acclimated animal compared to 
the warm acclimated animal. Blood flow to non-respiratory 
muscle is significantly less, and to BAT significantly more, 
in the cold acclimated animal (Foster and Frydman 1979; 
Foster and Frydman 1978a,b; Portet et al 1974; • Smith and
Horwitz 1969; Jansky 1968). The combined effects of an 
increased cardiac output and an increased fractional 
distribution to BAT results in a 25 fold increase in blood 
flow to BAT in the cold acclimated animal in response to 
cold. This substantial increase in blood flow to BAT is also 
believed to be of major importance in allowing the full 
thermogenic potential of BAT to be realised (Foster and 
Frydman 1978a).
1.2.3 The Role of Catecholamines in the Physiological 
Response to Cold
Studies of the regulatory mechanisms involved in the 
physiological response to cold point to a primary role for 
catecholamines in mediating both cardiovascular and metabolic 
responses (For review see Landsberg, Saville and Young 1984). 
Thus it is important to consider the effects of cold exposure 
on catecholamine release and the involvement of 
catecholamines in the physiological response to both acute 
and chronic cold exposure.
The primary physiological response to cold exposure 
and subsequent cold acclimation is the stimulation of the 
sympathetic nervous system (Young and Landsberg 1981) 
resulting in a marked rise in catecholamine secretion, 
predominantly noradrenaline, from the adrenergic terminals of 
sympathetic nerves and also from the adrenal medulla (Depocas 
and Behrens 1978; Young and Landsberg 1931). Levels of 
plasma noradrenaline are believed to reflect noradrenaline
release from sympathetic nerve terminals (Benedict, Fillez 
and Stanford 1977b). Picotti et al (1981) demonstrated a 
rapid increase in plasma noradrenaline levels within 5 
minutes of cold exposure, reaching a plateau after 30 minutes 
at a mean concentration of 514 pg/ml which is two times basal 
levels, whilst Benedict et al (1977a) showed a gradual rise 
of over four hours followed by a decline. Leduc (1961a,b), 
measuring urinary levels of noradrenaline, demonstrated a 
nearly maximum response after- 24 hours followed by a decline 
but still remaining 4 times control values after one month, 
whilst Leblanc and Nadeau (1961) showed a 5 fold increase in 
urinary noradrenaline after 7 months cold exposure. Of even 
greater relevance to this study are the findings of Young and 
Landsberg (1979) using a technique for the estimation of 
noradrenaline turnover rate and therefore a more direct 
measure of sympathetic activity . They were able to show an 
83% increase in pancreatic noradrenaline turnover rates in 
response to acute cold exposure. They also showed an 
increase in BAT noradrenaline turnover rates (Young, Saville, 
Rothwell, Stock and Landsberg 1982).
The well documented increases in sympathetic nervous 
activity and in plasma and urinary catecholamine 
concentrations observed during acute and chronic cold 
exposure suggest a functional involvement in the 
physiological response to cold as indicated below:
I) The role of catecholamines during acute cold 
exposure - Catecholamines appear to be involved in numerous 
physiological responses which serve to facilitate the 
maintenance of body temperature during acute exposure to
cold. Their lipolytic actions (Gray, Lickley and Vranic 
1980; Portet et al 1974) and glucogenic actions (Cryer 1983; 
Cherrington, Fuchs, Stevenson, Williams, ALberti and Steiner
1984) are well documented, as are their cardiovascular 
effects ie - stimulation of increased cardiac output and 
heart rate and readjustments in organ blood flow (Portet jet 
£1 1974 , Evonuk and Hannon 1963; Millard and Reite 1975).
II) The role of catecholamines in cold acclimation - 
There have been many studies demonstrating that the 
stimulation of NST is mediated via the release of 
noradrenaline from sympathetic terminals (Seydoux and 
Girardier 1978) resulting in beta adrenoceptor stimulation of 
brown fat cells (Shoenbaum, Johnson, Sellers and Gill 1966; 
Buckowiecki, Follea, Paradis and Collet 1980) which in turn 
stimulates the production of free fatty acids from 
triglyceride stores (Lafrance, Routhier, Tetu and Tetu 1979). 
There are also substantial data indicating that the 
development of NST occurs by virtue of an enhancement of this 
thermogenic response to noradrenaline (Jansky, Bartunkova and 
Zeisberger 1967), as reflected by an increased oxygen 
consumption or increased body temperature in response to 
adrenergic stimulation (Fregly, Field, Nelson, Tyler and 
Dasler 1977; Leblanc, Villemaire and Valliere 1969; Barney, 
Katovich, Fregly and Tyler 1980).
Similarly the greater increases in cardiac output and 
heart rate observed in response to cold in .the cold 
acclimated animal appear to be the result of an increased 
noradrenaline responsiveness (Evonuk and Hannon 1963; Foster 
et al 1980), whilst the altered fractional distribution of
cardiac output resulting in an increased blood flow to brown
adipose tissue (Foster et al 1980; Evonuk and Hannon 1963;
Fregly et al 1977; Portet et al 1974) appears to be the 
result of alterations in peripheral sensitivity to
catecholamines (Fregly et al 1977). Thus there is good
evidence to suggest that noradrenaline is involved in 
mediating the physiological responses to cold exposure in 
both warm and cold acclimated animals.
Adaptive alterations in thermogenic capacity in 
response to cold exposure are determined by the specific 
developmental BAT changes already discussed namely, increases 
in cell size and number, blood flow and mitochondrial 32K 
protein content. Suggestions that noradrenaline is involved 
in the development of these adaptive changes are supported by 
various studies: Mory, Ricquier, Nechad and Hemon (1982)
using chronic administration of guanethidine as a means of 
chemical sympathectomy were able to impair the BAT trophic 
response to chronic cold exposure ie - they demonstrated no 
increase in tissue mass, weak increases in DNA and protein 
content and suppression of mitochondrial development in terms 
of increased 32K protein and GDP binding. However attempts 
by Desautels and Himms-Hagen (1979) to mimic the effects of 
chronic cold exposure by chronic administration of 
noradrenline via intravenous injection were only able to 
induce growth in BAT and increases in protein and DNA 
content, but were unable to induce the changes in 
mitochondrial composition which would result in increased 
proton conductance pathways (ie increased 32K protein and 
GDP-binding). However more recent studies, possibly 
involving more effective administration of noradrenaline such
as with the use of miniosmotic pumps (Mory, Bouillaud, 
Combes-George and Ricquier 1984), implantation of 
phaeochromocytoma PC 12 tumours (Ricquier, Mory, Nechad, 
Combes-George and Thibault 1983) and the use of long acting 
sympathomimetics such as fenotorol (Young et al 1984b) were 
able to induce all the trophic responses caused by chronic 
cold exposure including the essential increases in
mitochondrial 32K protein and GDP-binding. Finally, repeated 
injections of isoproterenol (Leblanc, Valliere and Vachon
1972) mimicked the effects of cold acclimation in terms of
the noradrenaline-induced thermogenic response and
noradrenaline-stimulated increases in blood flow to BAT as 
well as the alterations in lipoprotein lipase activity in BAT 
as described by Carneheim et al (1984).
However it should also be noted that despite an
enhanced thermogenic response to noradrenaline in the cold 
acclimated animal, there is an apparent desensitisation of 
the beta receptor/adenylate cyclase system. Thus Bukowiecki, 
Follea, Valliere and Leblanc (1978) were able to show a 
down-regulation of beta adrenoceptor number on brown fat 
cells from the cold acclimated animal, whilst Svartengren, 
Svoboda and Cannon (1982) showed that these receptors became 
uncoupled from the adenylate cyclase system.
1.2.4 The Role of Glucagon in the Physiological Response to 
Cold
Rothwell and Stock (1984) have suggested that 
noradrenaline is solely responsible for the cold-induced 
changes outlined in the previous section, whilst Mory et al 
(1984) have stated that secondary effects of noradrenaline 
cannot be excluded. As numerous studies have identified 
glucagon as a hormone involved in the stress response (Bloom
1973) it is useful to consider the effects of cold exposure 
on glucagon secretion and to assess the possibility of a 
functional involvement of these changes in the physiological 
response to cold.
There have been numerous studies demonstrating the 
significant effects of cold exposure on plasma glucagon 
concetrations. Thus acute cold exposure has been shown to 
elevate basal plasma glucagon concentrations in man (Seitz et 
al 1981) and also in numerous other species including the 
rat, calf, piglet and sheep (Seitz et al 1981; Takahashi et_ 
al 1984; Takahashi 1984; Saski et al 1982). Prolonged 
exposure to cold in the rat has been shown to result in a 
temporary rise in glucagon concentration in mixed trunk blood 
after two weeks whilst after four weeks there was no 
significant difference between control and cold exposed 
plasma glucagon concentrations (Kuroshima and Doi 1976; 
Kuroshima, Doi and Ohno 1973).
Stuies in numerous species such as the piglet 
(Takahashi et al 1984), the calf (Takahashi 1984), the sheep
(Sasaki et al 1982) and the rat (Helman, Gilbert, 
Pfister-Lemaire, Reach and Assan 1984), have also 
demonstrated an enhanced glucagon response to arginine after 
both acute and chronic cold exposure. Also of interest are 
the data by Habara and Kuroshima (1983) showing an eight-fold 
increase in both insulin and glucagon binding by BAT after 
cold acclimation in the rat.
The mechanisms responsible for this increased glucagon 
secretion at low environmental temperature are unclear 
although evidence from studies of neural influences on the A 
cell suggest that increased secretion could be the result of 
sympathetic activation. Attempts to clarify the adrenergic 
mechanisms involved have produced inconsistent data. Both 
Sasaki et al (1982) and Helman et al (1984) in the sheep and 
rat showed no effect of beta blockade on the cold-induced 
increases in glucagon secretion, although both were able to 
reduce the acute cold-induced rise with the alpha adrenergic 
blocker phentolamine.
Although the role of glucagon in mobilising glucose 
through its effects on hepatic gluconeogenesis and 
glycogenolysis is well established (Park and Exton 1972), the 
role of glucagon in the mobilisation of free fatty acids is 
less clear. In vitro, the lipolytic effect of glucagon has 
been consistently observed (Himms-Hagen 1961; Joel 1966; 
Heckmayer, Barker, Duckworth and Solomon 1983; Lefebvre
1975). However, in vivo, this effect has sometimes been 
obscured by the antilipolytic effects of glucagon-induced 
insulin secretion (Shade, Woodside and Eaton 1979; 
Linjenquist, Bomboy and Lewis 1974; Arner, Bolinder and
Ostman 1983). Thus, under various experimental or clinical 
conditions resulting in low circulating insulin levels, the 
lipolytic action of glucagon is evident, as demonstrated in 
the insulin-dependent diabetic and during starvation (for 
review see Lefebvre 1975).
In relation to a specific role in the cold acclimated 
animal, the lipolytic actions of glucagon on BAT have been 
investigated. In vitro studies with isolated rat brown 
adipocytes have been able to demonstrate a lipolytic effect 
of glucagon (Joel 1966). Similarly in vivo studies in the 
rat by Kuroshima, Ohno and Doi (1977) monitoring free fatty 
acid levels in BAT venous blood as well as in systemic blood 
were able to demonstrate an increase in free fatty acid 
concentrations in BAT venous blood after an infusion of 
2ug/50ul of glucagon over a 5 minute period. No change was 
seen in systemic free fatty acid levels and it was suggested 
that this was the consequence of the insulinogenic effect of 
glucagon resulting in a suppression of lipolytic action.
Both of the above in vivo and in vitro studies were 
able to demonstrate an adaptive alteration in the BAT 
lipolytic response to glucagon in the cold acclimated animal. 
Thus Kuroshima et al (1977) were able to demonstrate an 
enhanced systemic lipolytic response to glucagon (tentatively 
explained as an enhanced response of peripheral tissues to 
glucagon), whilst in BAT venous blood, although an increase 
in free fatty acid levels was observed after glucagon 
infusion, the increase was smaller than that obtained in warm 
acclimated animals. From these data it was suggested that an 
increase in utilisation of free fatty acids within BAT of the
cold acclimated animal occurred in response to glucagon, thus 
implicating glucagon in the thermogenic response of BAT.
That glucagon may be involved through its lipolytic 
action in the stimulation of non-shivering thermogenesis has 
lead to numerous in vivo and in vitro studies into a possible 
calorigenic action. In vivo studies using a glucagon 
injection of 100pg/100g in the mouse and rat (Doi and 
Kuroshima 1981, 1982) and a glucagon infusion of
0.05pg/Kg/min for 15 min in the penguin (Barre and Rouanet 
1983) have all indicated an increase in oxygen consumption 
and body temperature, whilst in vitro studies using isolated 
rat brown adipocytes have also been able to show a 
calorigenic action of glucagon at a concentration of 1pg/ml 
(Kuroshima and Yahata 1979). Again all the above studies 
were able to show an enhanced response to glucagon in the 
cold acclimated animal. Other studies have also suggested a 
role for glucagon in the enhanced thermogenic response in the 
cold acclimated animal; Yahata, Habara and Kuroshima (1983) 
were able to demonstrate an enhanced cardiovascular response 
to a glucagon infusion of 2pg/min for 30 min in the cold 
acclimated rat, resulting in a raised cardiac output and 
enhanced blood flow to BAT similar to the cardiovascular 
responses elicited by noradrenaline, whilst chronic treatment 
of warm acclimated rats with glucagon, for a period of 6 
weeks (Yahata, Ohno and Kuroshima 1981), appeared to elicit 
all the developmental changes observed during cold exposure 
including the trophic BAT response and the enhanced 
thermogenic response to noradrenaline.
As the basal range of glucagon in mixed trunk blood of
the rat is of the order of 200 pg/ml (Kuroshima and Doi
1976), the doses of glucagon used to achieve these effects 
has lead to doubt over the physiological significance of such 
actions in vivo, although recent studies by Habara and 
Kuroshima (1983) indicating a marked increase in the glucagon 
content of BAT of the cold acclimated rat do suggest a 
functional involvement. Similar increases in BAT insulin 
content were also demonstrated in agreement with studies 
demonstrating an enhanced BAT sensitivity to insulin in 
response to cold acclimation, with indications that insulin 
is involved in the BAT thermogenic response (Seydoux, 
Trimble, Boillaud, Assimacopoulos-Jeannet, Bas, Ricquier, 
Giacobino and Girardier 1984). Other studies have also shown 
an enhanced hepatic and peripheral responsiveness to insulin 
in the cold acclimated animal (Cunningham, Gulino, Meara and 
Bode 1985; Weekes, Sasaki and Tsuda, 1983).
Evidence of other thermogenically active hormones such 
as ACTH and the iodothyronines (Heim and Hull 1966; Joel 
1966) and data indicating attenuation of the calorigenic 
action of glucagon in the thyroidectomised and 
adrenomedullated animals (Yahata and Kuroshima 1982) suggest 
that glucagon may act synergistically with other lipolytic 
hormones. Thus it is possible that the thermogenic response 
to cold in the cold acclimated animal is the result of a 
multifactorial regulation within which glucagon might be a 
contributory factor.
1.3 The Autonomic Regulation of Glucagon Secretion
In view of the evidence indicating a sympathetically 
mediated rise in glucagon secretion in response to cold 
exposure it is clearly important to consider the mechanisms 
of autonomic regulation within the pancreas and, in 
particular, of the A cell.
Many lines of evidence indicate neural regulation of 
endocrine pancreatic secretion. Morphological evidence shows 
the presence of adrenergic, dopaminergic and cholinergic 
nerve terminals on or near islet cells (For review see Woods 
and Porte 1974). Functional evidence in support of a role 
for these nerve endings has been obtained by stimulation 
(Bloom and Edwards 1978; Andersson, Holst and Jarhult 1982), 
section (Bloom, Edwards and Vaughan 1974) and pharmacological 
interruption (Bloom and Edwards 1978; Andersson et al 1982; 
Kaneto, Kajinuma and Kosaka 1974) of the autonomic pathways 
to the pancreas.
1.3.1 Sympathetic Nervous System
It is known that pancreatic A and B cells possess both 
alpha and beta adrenergic receptors, with evidence that the A 
cells possess predominantly beta receptors whilst the B cells 
possess predominantly alpha receptors (Iversen 1973a; Sarnols 
and Weir 1979). It can therefore be assumed that both the A 
and the B cell are susceptible to sympathetic stimulation.
Electrical stimulation of splanchnic nerve fibres,
which provide sympathetic innervation to the pancreas,
stimulates glucagon release from islet A cells with 
concomittant inhibition of insulin release from islet B
cells, in many species including dogs, sheep, cats, calves 
and rats (Bloom and Edwards 1978; Andersson et al 1982; 
Kaneto et al 1975; Bobbioni, Marre, Helman, and Assan 1983). 
Administration of phentolamine (to provide alpha adrenergic 
blockade) and propranolol (to provide beta adrenergic 
blockade) in conjunction with, or prior to, electrical 
stimulation of splanchnic nerve fibres has produced 
conflicting evidence as to the adrenergic mechanisms involved 
in this sympathetically induced release of glucagon. Studies 
by Bloom and Edwards (1978) in the anaesthetised calf, and by 
Andersson et al (1982) in the anaesthetised cat showed no 
effect of alpha and beta blockade on splanchnic nerve 
stimulated glucagon release. However Kaneto et al (1975b) 
showed in the dog, that propranolol caused both a marked 
decline in basal plasma glucagon levels and a marked initial 
decrease, at the onset of stimulation, of glucagon output. 
However it must be noted that glucagon output still showed a 
vigorous increase with continued stimulation.
Another means of eliciting glucagon release via neural 
mechanisms involves generalised activation of the autonomic 
nervous system, such as with exercise (Harvey, Faloona and 
Unger 1974), immobilisation stress (Nakhooda, Sole and 
Marliss 1981), 2-deoxyglucose and insulin-induced hypoglyce 
mia (Bloom, Edwards and Vaughan 1974; Bloom, Edwards and 
Hardy 1978; Asplin, Werner, Halter, Hollander and Palmer 
1985) and hypoxia (Bloom et al 1978; Bloom, Edwards, Hardy
and Silver 1976). All of these caused significant 
stimulation of glucagon secretion. The use of alpha 
adrenergic and beta adrenergic blockers to determine the 
mechanism of adrenergic A cell stimulation under such 
conditions has provided conflicting results.
The involvement of both alpha and beta adrenergic 
receptors in stimulating glucagon release in response to 
2-deoxyglucose induced hypoglycemia was demonstrated by 
attenuation of this response after administration of 
phentolamine and propranolol in the baboon (Asplin et al
1985). Nakhooda et al (1981) using immobilisation stress in 
rats to elevate plasma glucagon levels showed that 
phentolamine, but not propranolol, attenuated stress-induced 
increments in plasma glucagon, leading to the postulation of 
a stimulatory alpha adrenergic effect on the A cell of the 
rat. Harvey et al (1974) came to the same conclusion when he 
showed that exercise-induced hyperglucagonemia in the rat was 
abolished by prior treatment with phentolamine. However, 
under identical conditions Luyckx and Lefebvre (1974) showed 
the converse, with propranolol, rather than phentolamine, 
abolishing the exercise-induced hyperglucagonemia and also 
demonstrating an elevation in resting plasma glucagon levels 
after treatment with phentolamine, suggesting a basal 
inhibitory control of glucagon via the alpha adrenergic 
receptor. However, in the sheep, Brockman (1985) 
demonstrated an exercise induced increase in glucagon that 
was unaffected by combined adrenal denervation and alpha 
blockade.
Further studies have been undertaken to investigate
the direct effect of sympathetic neurotransmitters and 
various sympathetic agonists and antagonists on glucagon 
release from the pancreas, thus allowing investigation of the 
role of the specific adrenergic receptor mechanisms involved. 
Studies with adrenaline and noradrenaline have shown a 
stimulatory effect of these catecholamines on glucagon 
secretion and a concomittant inhibitory effect on insulin 
release in the dog in vivo (Ribes, Trimble, Blayac, Wollheim 
and Loubatieres-Mariani 1984; Raum, Serdloff, Garner, Laks 
and Laks 1984) and in vitro, using the isolated perfused rat 
pancreas (Weir, Knowlton and Martin 1974), and dispersed rat 
islets (Iversen 1973a; Sorenson, Elde, and Seybold 1979). 
Whilst there is good evidence to suggest adrenergic 
inhibition of insulin secretion occurs via the 
alpha-adrenergic receptor (Nakai, Nakadate and Kato 1980) 
with a stimulatory effect of beta-adrenergic agonism (For 
review see Woods and Porte 1974), there is considerable 
disagreement over the receptor mechanisms involved in 
adrenergic stimulation of the A cell.
The use of numerous adrenergic agonists and 
antagonists has allowed a more detailed study of adrenergic 
control of the A cell with much, although not all, evidence 
pointing to beta adrenergic activation of A cell secretion. 
The beta antagonist propranolol has been shown to abolish the 
noradrenaline-induced rise in glucagon secretion in vitro in 
the dog (Iversen 1973a), whilst the pure beta agonist 
isoproterenol elicits a rise in glucagon secretion in vivo in 
the dog (Kaneto, Miki and Kosaka 1975) and in man (Gerich, 
Langlois, Noacio, Schneider and Forsham 1974) and in vitro in 
the dog (Iversen 1973a; Kaneto et al 1975a). However there
have also been studies demonstrating an inhibitory effect of 
beta adrenergic agonism such as those by Tyler and Kajinama 
(1972) in the duck, and Toyota, Sato and Kudo (1975) in the 
rat, using the beta agonist isoproterenol.
The role of the alpha receptor in control of glucagon 
is even more confused. Gerich et al (1974b) using the alpha 
antagonist phentolamine.in the presence and absence of the 
specific alpha agonist methoxamine in vivo in man, suggested 
an inhibitory role for the alpha receptors, with some 
evidence for the existence of intrinsic inhibitory adrenergic 
tone. Similarly Narimiya, Yamada, Matsuba, Ikeda, Tanese and 
Abe (1981), using the isolated perfused rat pancreas, was 
able to inhibit glucagon release using the specific alpha 
agonist phenylephrine, although the use of the alpha 
antagonist phentolamine in this study and others (Iversen 
1973a) did not produce the expected increase in glucagon 
secretion which would be associated with the removal of any 
putative alpha adrenergic inhibition. Finally studies by 
Knudtzon (1984) in the rabbit using selective alpha and beta 
antagonists indicated that adrenaline induced rises in 
glucagon secretion were mediated by alpha-2 mechanisms.
1.3.2 The Parasympathetic Nervous System
The effect of the parasympathetic branch of the 
autonomic nervous system on A and B cell function has been 
studied both in vivo (Bloom et al 1974a,b; Bloom, Vaughan 
and Russel 1974; Bloom et al 1978; Ahren and Taborsky 1986)
and in vitro (Kaneto and Kosaka 1974). Stimulation of the 
parasympathetic system has been shown to elicit both glucagon 
and insulin release. This has been shown by electrical 
stimulation of the distal cut ends of the thoracic vagi of 
the rat (Bobbioni et al 1983) and the dog (Ahren and Taborsky
1986), whilst truncal vagotomies caused a reduced glucagon 
release in response to hypoglycemia in the calf (Bloom et al 
1974b). The use of acetylcholine and atropine both in vivo 
in the dog (Kaneto and Kosaka 1974) and in vitro in the rat 
(Honey and Weir 1980) have provided further evidence of the 
involvement of the parasympathetic nervous system in the 
regulation of glucagon secretion. In vivo studies in the dog 
(Kaneto and Kosaka 1974) have shown that infusions of 
acetylcholine serve to elevate plasma glucagon levels whilst 
prior treatment with atropine abolishes this response. The 
same response is seen using the isolated perfused canine 
pancreas where Iversen (1973b) showed the stimulatory effects 
of acetylcholine on glucagon and insulin secretion and the 
inhibitory effects of atropine. Thus it is well established 
that both the sympathetic and parasympathetic branches of the 
autonomic nervous system play a role in controlling glucagon 
release. However it is important to elucidate what role they 
play and under what circumstances they operate to control 
glucagon release.
Bloom et al (1978) have postulated distinct roles for 
the two branches of the autonomic system. Using stimuli of 
hypoxia (Bloom et al 1978) and hypoglycemia (Bloom et al 
1974b; Bloom et al 1978) in the conscious calf, Bloom showed 
that although both branches of the autonomic nervous system 
were involved in control of glucagon release, the
parasympathetic system seemed more sensitive to the specific 
stimulus of hypoglycemia whilst sympathetic stimulation of 
glucagon release seemed to be a response to more general 
non-specific stressful stimuli (Bloom 1973).
Thus in conclusion it can be said that there is 
substantial evidence to indicate separate roles for the two 
branches of the autonomic mervous system in the control of 
glucagon secretion; the parasympathetic system being 
involved in physiological homeostatic regulation of blood 
glucose, with sympathetic activitation of the A cell 
occurring during extreme, stressful situations associated 
with increased energy need. In this context the role of 
sympathetic activation in mediating the cold-induced changes 
in glucagon secretion are particularly relevant to this 
study.
In considering sympathetically-mediated effects of 
cold exposure it is important to consider other factors that 
might modulate the A cell response to sympathetic inputs. 
There is much evidence to indicate regulatory interaction 
between insulin and glucagon at the pancreatic islet level, 
thus it is useful to assess the extent to which such 
paracrine influences may be involved in altered glucagon 
secretion patterns associated with cold exposure.
1.4 Paracrine Influences
The islets of Langerhans consist of highly organised 
communities of peptide^secreting cells (Orci and Unger 1975) 
responsible for the mobilisation and deposition of energy 
substrates within the body (Unger, Rouiller and Orci 1980; 
Boden, Rezuani and Owen 1984; Cryer, Tse, Clutter and Shad 
1984). This is achieved by a finely controlled balance of 
glucagon, insulin and somatostatin release from the A, B and 
D cells respectively. For the islets to behave as an 
integrated regulatory unit, close coordination of all three 
secretory products is obviously required and there is 
convincing evidence to suggest that the islets themselves are 
involved in coordination of the relative hormonal output from 
the pancreas (For review see Unger 1983, 1985).
1.4.1 Intra-Islet Interactions
Evidence of inhibition of the A cell by insulin comes 
from numerous studies. In vivo studies by Muller, Faloona 
and Unger (1971) with dogs, in which experimental diabetes 
has been induced by administration of alloxan or 
streptozotocin, demonstrated that the concurrent 
hyperglycemia and hyperglucagonemia produced in the diabetic 
animal could be reduced by infusion of physiological 
concentrations of insulin. In vitro studies by Ostenson 
(1979) using incubated A cell-rich (dorsal) guinea-pig islets 
also showed a suppression of glucagon release by insulin.
However there is disagreement as to the mechanism of 
insulin-induced inhibition of glucagon secretion and whether 
it is mediated via insulin-stimulated glucose uptake and 
catabolism within the A cell. Certainly Ostenson (1979) 
showed in vitro, that insulin only inhibited glucagon release 
in the presence of glucose. He also demonstrated that 
insulin stimulated glucose utilisation within the A cell as 
well as increasing intracellular ATP concentrations and 
concluded that the A cell suppression by insulin was an 
energy-requiring process involving increased utilisation of 
glucose. However Samols and Harrison (1976) demonstrated in 
the isolated canine pancreas that suppression of insulin 
output could occur in the absence of glucose, whilst 
Pipeleers, Schuit, Van De Schravendijk and Van De Winkle
(1985) using purified rat A cell preparations, showed a 
relative insensitivity to insulin compared to somatostatin, 
with a partial inhibitory action of insulin affecting only 
adrenaline-stimulated glucagon secretion.
The stimulatory effects of exogenous glucagon on 
insulin secretion are similarly well documented. Samols
(1965) and Samols, Marri and Marks (1966) showed a pronounced 
increase in insulin release in human subjects after an 
intravenous injection of 1mg of glucagon; this rise was 
independent of blood glucose concentrations as the insulin 
rise occurred prior to any change in arterial blood glucose, 
although there was an apparent augmentation of this 
insulinemic effect of glucagon in the presence of glucose. 
Similarly, increased insulin release in response to pulse 
administration of glucagon has been demonstrated in vitro 
using the isolated perfused pancreas of the rat (Grodsky,
Bennett and Smith 1967) and the rabbit (Turner and McIntyre
(1966), again independent of glucose concentrations.
There are also many studies which have demonstrated 
the inhibitory effect of exogenous somatostatin on glucagon 
and insulin release (for review see Guillemin and Gerich 
1976). This effect has been demonstrated in numerous species 
of animals including baboons (Koerker, Ruch, Chideckel, 
Palmer, Goodner, Ensinck and Gale 1974) and dogs (Smith, Mei 
Chen, Woods, Ensinck and Porte 1978). It has also been 
demonstrated in vitro using the isolated perfused pancreas of 
the dog (Iversen 1974) and rat (Weir, Shwarz and Mathe 1980).
Many studies have indicated a physiological role of 
paracrine influences within the islets. A functional 
inhibitory role for insulin in controlling A cell secretion
has been indicated in vivo in man using a technique of
insulin-induced B cell suppression which resulted in an 
enhanced A cell response to arginine (Asplin, Paquette and 
Palmer 1981). In vitro studies using the isolated perfused 
pancreas of the streptozotocin diabetic rat have indicated 
that simulation of the normal glucopenia-induced decline in 
insulin partially restores the glucagon response to
glucopenia, which is otherwise absent in the streptozotocin
diabetic rat (Tominaga, Maruyarna, Bolli, Hederman and Unger
(1986), whilst studies using collagenase-dispersed rat islets 
indicated enhanced glucagon secretion when compared to intact 
islets (Pipeleers, Veld, Maes and Van de Winkel 1982; 
Fletcher, Grogan, Barras and Weir 1983). Pipeleers et al 
(1985b), using isolated A cell preparations, have since 
demonstrated a relatively minor inhibitory effect of insulin
on the A cell, acting only on adrenaline-mediated stimulation 
of glucagon release and were unable to show the existence of 
insulin receptors on the A cell. Other receptor binding
studies,however, have shown a significant degree of insulin 
binding receptors on the A cell (Patel, Amherdt and Orci
1982).
Other studies have demonstrated a decreased B cell 
secretion and responsiveness in purified B cell preparations 
compared to intact islets (Hopcroft, Mason and Scott 1985; 
Pipeleers, Schuit, in’t Veld, Maes, Hooghe-Peters, Van De 
Winkle and Gepts 1985; Pipeleers et al 1982). Studies by 
Baetens, Malaiss-Lagae, Perrelet and Orci (1979), indicating 
A cell rich areas within the dorsal pancreas of the rat in
contrast to the sparse A cell population within the ventral
pancreas, have led to work using isolated islets from either 
region to further investigate paracrine function (Trimble, 
Halban, Wollheim and Reynold 1982; Trimble and Reynold
1981). It was found that the greater proportion of A cells
within the dorsal islets was associated with higher rates of 
glucose-induced insulin release than in the ventral islets 
and that exogenous glucagon could eliminate the difference in 
insulin release between the two regions. This suggests a 
primary role for glucagon in the intra-islet regulation of 
insulin release.
Studies by Schuit and Pipeleers (1985), using isolated 
B cell preparations, have since shown a role for endogenous 
glucagon in maintaining elevated cAMP levels within the B
cell, which were shown to be essential for glucose
stimulation of insulin release. Receptor-binding studies
(Van Schravendijk, Foriers, Hooghe-Peters, Rogiers, De Meyts, 
Sodoyez and Pipeleers 1985) confirmed the presence of 
glucagon binding sites on the B cell with binding 
characteristics similar to those of isolated hepatocytes 
although the B cells had fewer glucagon receptors per cell.
1.4.2 Mechanisms of Islet-Cell Interaction
Although the influences of insulin, glucagon and 
somatostatin on islet cell secretion are well documented, the 
mechanisms of islet-cell interaction remains unclear. 
Morphological studies suggest functional subdivision of the 
islets (Orci and Unger 1975). Glucagon secreting A cells 
have been shown to form the outer rim of the cortex of the 
islets and make up approximately 25% of the dorsal endocrine 
pancreas (Orci, Baetens, Rufener 1976). There is also data 
indicating greater concentration of A cells within the dorsal 
pancreas compared to the relatively sparse A cell population 
within the ventral pancreas, where polypeptide-P containing 
C-cells appear to replace them (Baetens et al 1979; Orci, 
Baetens, Ravazzola, Stefan and Malaisse-Lagae 1976). 
Insulin-containing B cells constitute at least 60% of the 
islet and form its medulla (Orci et al 1976a). Somatostatin- 
containing D cells are situated between A and B cells and 
form approximately 10% of the islet cells (Orci et al 1976b). 
Within the heterocellular cortex A, B and D cells are 
topographically contiguous with each other, which has raised 
the possibility of cell-cell interaction occurring through 
gap junctions as well as paracrine actions (Unger and Orci
1981).
Intercellular communication via gap junctions (a 
network of membrane specialisations thought to be involved in 
cell-cell metabolic coupling and electrotonic coupling) is 
supported by indirect evidence indicating the existence of 
such structures between A and B cells (Orci, Malaisse-Lagae, 
Ravazzola, Rouiller, Renold, Perrelet and Unger 1975).
Other membrane specialisations knows as tight 
junctions (formed by fusion of the outer' layers of adjacent 
membranes (Orci et al 1975) were initially postulated as a 
means of compartmentalisation of the islet interstitium, 
enabling islet secretory products to be channelled past 
adjacent cells (Orci, Amherdt and Henquin 1973). However 
Kawai, Ipp, Orci, Perrelet and Unger (1982) observed in the 
isolated perfused canine pancreas, that concentrations of 
somatostatin 10-15% of that found in the pancreatic vein, 
caused a significant inhibition of insulin and glucagon 
secretion, with similar though less striking results found 
with glucagon. This lead to the suggestion that high 
concentrations of locally secreted somatostatin are not in 
contact with somatostatin receptors of the A and B cells and 
that the interstitium of the islets was compartmentalised 
possibly by means of tight junctions so that hormones 
secreted into the venous circulation did not have access to 
the interstitial space containing arterial-side receptors of 
the affected islet cell. This would enable low levels of 
circulating somatostatin and glucagon to exert an ongoing 
influence on the B cell.
Studies by Bonner-weir and Orci (1982) on islet 
microcirculation showed that afferent arterioles of the 
islets first penetrate deep into the B cell-rich centre of 
the islet before forming centrifugally radiating networks of 
capillaries that perfuse the A and D cell-rich cortex and 
then reassemble into collecting venules. It was pointed out 
that this arrangement would mean; 1) that the B cells would 
be the first to receive glycemic stimuli, 2) that insulin
concentrations perfusing the A cells would be the highest in
the body and 3) that the B cells would be exposed to systemic 
concentrations of glucagon and somatostatin.
Such an anatomical arrangement would enable insulin to 
act directly on the A cell whilst, because of
compartinentalisation of the pancreatic interstitium , the A 
cell could only act on the B cell via the systemic 
circulation. This would skew the insulin-glucagon feedback 
system in favour of the inhibitory influence of insulin on 
the A cell and reduce the importance of the stimulatory
action of glucagon on the B cell. This has lead to the 
suggestion by Unger (1983) that insulin might function as a 
major release inhibiting factor for glucagon, although the 
recent studies by Pipleers et al (1985b) do not support this.
1.5 Substrate Regulation
The prime function of islet secretion in the 
regulation of normal fuel homeostasis requires appropriate 
responses of both A and B cells to a spectrum of 
physiological events. The overriding signal to both A and B 
cells appears to be the ambient glucose concentration 
although other subtrates are also potent modulators of 
glucagon and insulin secretion. Consideration of these 
modulating influences is clearly important in assessing the 
net effects of lowered environmental temperature on glucagon 
secretion.
1.5.1 Glucose
Changes in ambient plasma glucose concentrations 
elicit reciprocal responses of insulin and glucagon (Gerich, 
Charles and Grodsky 1974) and also determine the magnitude of 
response to other stimuli (Gerich et al 1974; Pagliara, 
Stillings, Hover, Martin and Matchinsky 1974; Ostenson and 
Grill 1985). The mechanism by which changes in extracellular 
glucose concentration influence glucagon secretion is 
controversial (For review see Unger et al 1985). In support 
of the theory that insulin functions as the major release 
inhibiting factor for glucagon comes evidence indicating that 
the A cell response to glucose is mediated by insulin. 
Certainly situations of hyperglycemia in the absence of 
insulin both in vivo (Muller et al 1971) and in vitro
(Maruyama, Hisatomi^ Orci, Grodsky and Unger 1984), do not 
result in the expected suppression of glucagon release, 
whilst the partial restoration of the glucagon response to 
glucopenia can be achieved by the simulation of the normal 
glucopenia induced decline in insulin (Tominaga et al 1986). 
However, this apparent glucose unresponsiveness of the A cell 
(Leahy and Weir 1985) has been explained by Starke, Grundy, 
McGary and Unger (1985) who have suggested that the ambient 
hyperglycemia produced by ' insulin lack results in a glucose 
unreponsiveness of the A cell. Thus the hyperglucagonemia of 
insulin-deficient alloxan diabetic dogs, when made 
normoglycemic by treatment with the glucuretic agent 
phloridzin, responded normally to increments in glucose. 
Other studies have also suggested that the A cell might not 
depend solely on insulin for its response to glycemic 
stimuli. Gerich et al (1974a) showed in the isolated 
perfused pancreas that the A cell was more sensitive to the 
suppressive effects of glucose than the B cell was to its 
stimulatory effects, thus glucose-inhibition of glucagon was 
taking place in the virtual absence of insulin. Similarly 
Leclercq-Meyer, Marchand and Malaisse (1983) showed that 
whilst insulin may be involved in determining the magnitude 
of glucose suppression of glucagon secretion, the rate of 
recovery of A cell secretion after termination of the 
glycemic stimulus was solely dependent on the magnitude and 
length of the glucose pulse. Similar evidence of an A cell 
response to glycemic stimuli independent of insulin has been 
provided by Pagliara et al (1974) and Asplin, Raghu, Dornan 
and Palmer (1983). Pipeleers et al (1985b), again using 
purified A cell preparations, demonstrated a direct 
insulin-independent inhibition of arginine-stimulated
glucagon release by glucose.
It has also been suggested (Hisatomi, Maruyama, Orci, 
Vasko and Unger 1985) that glucose suppression of glucagon 
may also be mediated partly via an intrapancreatic alpha- 
adrenergic mechanism which operates independently of the 
central nervous system. Further studies are obviously 
required to clarify the mechanisms involved in
glucose-inhibition of glucagon secretion.
1.5.2 Amino Acids
As secretogogues, amino acids are unusual in causing 
simultaneous stimulation of both A and B cell secretion 
(Gerich et al 1974; Pagliara et al 1974; Pek, Tai and 
Crowther 1976; Pagliara, Stillings, Haymond, Hover and 
Matschinsky 1975), although in general they appear to be a 
more potent stimulator of the A cell than the B cell (Gerich 
et al 1974). Individual amino acids differ in their ability 
to stimulate glucagon secretion. Whilst arginine is the most 
potent single amino acid secretogoue (Assan, Attali, 
Ballerio, Boillot and Girard 1977), a physiological mixture 
of numerous amino acids has been shown to be a more potent 
secretogogue of islet secretion than an equimolar 
concentration of any single amino acid (Assan et al 1977; 
Pagliara et al 1974). The potency of“ such a mixture is 
compatible with the role of circulating amino acids in 
regulating pancreatic secretion in vivo (Unger, Ohneda, 
Aguila-Parada and Eisentraut 1969).
Many other studies using the isolated perfused rat 
pancreas have shown that arginine elicits a biphasic release 
of glucagon and insulin. Gerich et al (1974) showed that an 
arginine concentration as low as 1mM could stimulate the 
release of glucagon, although because of the suppressive 
effects of glucose, a concentration of greater than 3 mM 
arginine was required at a physiological glucose 
concentration of 5.5 mM. In contrast, aminogenic insulin 
release in the absence of glucose only occurred at 6 mM 
arginine with a monophasic release. Thus in vitro amino
acids have far less effect on insulin than on glucagon 
secretion, contrasting with the in vivo situation where the 
presence of physiological glucose concentrations serves to 
augment insulin secretion.
1.5.3 Lipids
As with insulin, the role of plasma lipid 
concentrations in regulating glucagon secretion is uncertain. 
Muller, Aoki, Flatt, Blackburn, Egdahl and Cahill (1976) 
failed to demonstrate any suppressive effects of elevated 
plasma free fatty acids, glycerol or beta hydroxybutyrate 
levels on glucagon secretion in the dog in vivo. However 
many workers have shown an inhibitory effect of elevated 
plasma free fatty acid levels on glucagon secretion in vivo; 
both in man (Hicks, Taylor, Vij, Knopt, Floyd and Fajans, 
1977; Andrews, Lopez and Blackard 1975; Gerich, Langlois, 
Noacco, Loremi, Kararn and Forsham 1976), in ducklings 
(Foltzer, Strosser, Harvey and Mialhe 1985) and in the dog
(Madison, Seyffert, Unger and Barner 1968; Luyckx and 
Lefebvre 1970), although Hicks et al (1977) and Andrews et al 
(1975) were unable to show an inhibitory effect of free fatty 
acids on arginine-stimulated glucagon secretion. Luyckx and 
Lefebvre (1970) also demonstrated a marked rise in glucagon 
secretion in response to a fall in plasma free fatty acid 
concentrations. In vitro studies have been able to 
demonstrate a similar regulating influence of free fatty 
acids (Campillo, Luyckx and Lefebvre 1982; Edwards and 
Taylor 1970).
1.6 Experimental Techniques for the Study of Pancreatic 
Function
Investigations into the regulatory mechanisms involved 
in the control of pancreatic function require rigid, 
controlled conditions that are not easily attainable in vivo. 
Thus numerous in vitro methods have been developed in order 
to achieve control over the numerous interactive factors that 
influence pancreatic secretion. However, as a consequence of 
this, experimental conditions are inevitably less 
physiological - an important consideration in the selection 
of an appropriate in vitro technique.
1.6.1 Isolated Islet Cells
Recently a method of autofluorescent cell sorting has 
been developed for the preparation of dispersed isolated 
purified islet cells (Pipeleers,in't Veld, Van De Winle, 
Maes, Schuit and Gepts 1985a). Such preparations are 
invaluable in assessing the specific response of pancreatic 
islet cells in the absence of interaction between cell types 
(ie - in the absence of paracrine influences). However these 
preparations, as yet, are not sensitive enough to monitor 
short term alterations in release activity, neither do they 
provide information about the dynamics of the secretory 
response.
1.6.2 Isolated Islets
The development of methods for the dispersal and 
isolation of pancreatic islets (Lacy and Kostianovsky 1967) 
has allowed the use of such isolated islet preparations in 
both static incubation and perifusion systems (Moskalewski 
1965; Lacy, Walker and Fink 1972). These methods have the 
advantage of allowing numerous simultaneous studies using a 
single pancreas, also, unlike earlier in vitro methods 
utilising tissue slices (Assan, Plouin, Girard, Slama, 
Houtecouverture and Buneaux 1975), the islets are entirely 
free of exocrine pancreatic tissue and therefore the 
associated problems of contamination with exocrine 
proteolytic enzymes are obviated. However there is complete
disruption of the pancreatic vasculature, so that passage of 
substances in and out of the islets must depend solely on the 
process of diffusion, and whilst the preparation procedure is 
relatively shorter and simpler than the extensive procedures 
invoved in the preparation of isolated cell types there is 
still a substantial degree of trauma involved as the result 
of mechanical and enzymatic dispersal of the islets.
1.6.3 The Isolated Perfused Pancreas
This method involves isolation of the pancreas as an 
organ block and perfusion with blood or a synthetic medium 
with collection of the effluent via the cannulated hepatic 
portal vein (Sussman, Vaughan and Timmer 1966; Grodsky, 
Batts, Bennett, Vcella, Williams and Smith 1963; 
Loubatieres, Alric, Mariani and Chapel 1972). The advantages 
of perfused pancreas preparations over other techniques used 
in vitro are summarised by Ross (1972) as follows:
1) Superficial and deep islets are equally provided 
with oxygen and nutrients which are constantly 
replaced. Substrates and effectors arrive at the 
cells by the physiologically normal route.
2) The islets remain in anatomical relationship 
with other cells and tissues of the organ, 
including blood vessels and intrinsic nerves.
3) Only extrinsic nerve control is lost, any part
which intrinsic nerves play in regulating islet 
function may be preserved.
4) There is the possibility of a control and an 
experimental period of study in the same pancreatic 
preparation.
Thus the isolated perfused pancreas was selected to 
allow the study of glucagon secretion using an intact organ 
system within which there is normal paracrine interaction and 
an intact pancreatic vascular system, whilst involving 
minimal preparatory trauma. Using the isolated perfused 
pancreatic preparation an investigation was carried out in an 
attempt to determine the effects of chronic cold exposure on 
glucagon secretion and to elucidate the possible adrenergic 
regulatory mechanisms that might be involved. The following 
experiments were performed:
1) Time course effects of chronic cold exposure - 
Investigations of changes in basal and arginine 
stimulated glucagon and insulin secretion from the 
isolated perfused rat pancreas of animals subjected 
to varying periods of cold exposure.
2) Dose response effects of noradrenaline in the 
warm and cold acclimated rat - Investigations of 
the dose-response effects of perfusion with 
increasing concentrations of noradrenaline on basal 
and arginine-stimulated glucagon release from the 
isolated perfused pancreas of the warm and cold 
acclimated rat.
3) Adrenergic regulation of glucagon secretion in 
the warm and cold acclimated rat - Investigation 
into changes in basal and arginine stimulated 
glucagon secretion from the isolated perfused 
pancreas of warm and cold acclimated rats treated 
chronically with the adrenergic blocking agents 
phentolamine or propranolol.
2 THE ISOLATED PERFUSED PANCREAS - MATERIALS AND METHODS
2.1 Introduction
Two groups of workers are mainly credited with the 
development of methods of pancreatic perfusion. Sussman et 
al (1966) used pancreatic tissue completly separated from 
surrounding organs while Grodsky et al (1963) and Loubatieres 
et al (1972) left the stomach, spleen and duodenum attached. 
Diluted blood or bicarbonate buffered medium was infused 
through the aorta or coeliac axis, and effluents were 
collected from the portal vein. These media were either 
recycled or allowed to collect after a single passage, 
substances under study being incorporated in the recycled 
medium or injected as a pulse for a single passage through 
the tissue.
The isolated perfused pancreatic preparation selected 
for this investigation involved the isolation of the pancreas 
within a tissue block incorporating the stomach, spleen and 
duodenum (Loubatieres et al 1972), so as to avoid excessive 
trauma to the pancreas as the result of extensive dissection 
and to retain areas of the organ that might otherwise be lost 
due to the diffuse nature of the rat pancreas. Synthetic 
perfusion medium was chosen in preference to whole or diluted 
blood in order to avoid the problems of proteolytic breakdown 
of glucagon and the associated problems involved in the 
radioimmunoassay of plasma glucagon (Unger and Eisentraut
1968).
In synthetic perfusion media the maintenance of 
colloidal pressure is accomplished by use of plasma 
substitutes or expanders such as albumin, gelatine or dextran 
(Ross 1972) for pancreatic perfusion experiments. The simple 
exposition of Starlings law is that blood circulating through 
a capillary bed loses fluid to the interstitial space when 
the hydrostatic pressure within the capillary exceeds the sum 
of the external tissue pressure and the colloidal osmotic 
pressure within the lumen of the vessel. Since the 
hydrostatic pressure drops between the arterial and venous 
ends of the capillary, fluid is lost at the former end then 
regained at the latter end. In perfusion experiments, the 
artificial medium and perfusion pressure should be selected 
to achieve a similar balance, so that a net fluid loss from 
the vascular compartment does not occur.
2.2 Experimental Animals
Male Wistar albino rats (Rattus norvegicus) were used 
in all experiments. This species was chosen since it was the 
most commonly used in reported works studying the effects of 
cold exposure or involving the use of the isolated perfused 
pancreas. Males were used because they have a less variable 
endocrine physiology than females. The average age of the 
rats at the time of sacrifice was.12 weeks when they weighed 
between 250 and 350g. They were separated into two main 
groups.
2.2.1 Warm Acclimated Animals
These were kept 6 in a cage (20cm by 30cm by 50 cm) in 
the animal house at a room temperature of 2 2 + 1  °Cf with a 
constant 12 hour photoperiod from 0800 hours GMT to 2000 
hours GMT. They received food (Spratts Small Animal Diet 
No.1) and water ad libitum.
2.2.2 Cold Exposed Animals
These were kept 6 in a cage (20cm by 30 cm by 50cm) in 
a constant temperature room at 4 °C with the same photoperiod 
as control rats. They received food, as above, and water ad 
libitum.
For use in the study of the time course effects of 
cold exposure, the cold exposed rats were divided into three 
groups according to the period for which they were kept at 4 
°C.
1)2 weeks cold (referred to as Cold 2 group)
2) 4 weeks cold (referred to as Cold 4 group)
3) 6 weeks cold (referred to as Cold 6 group)
In all other experiments all cold exposed animals used 
were kept at 4 °C for a period of 6 weeks and are referred to
as the cold acclimated animal groups.
2.2.3 Rats Treated With Adrenergic Blockers
Rat groups (warm or cold acclimated) selected for 
treatment with adrenergic blockers received:
Phentolamine - 0.125 mg/kg (Rogitine CIBA - made up 
as 0.125 mg/ml in 0,9% saline) given by 
subcutaneous injection twice daily at 9.00 and
21.00 for 7 days (Baroody 1979).
Propranolol - 0.7 mg/kg (Inderal ICI - made up as a 
solution of 1 mg/tnl in a 0.04 M phosphate buffer pH 
7) given by subcutaneous injection twice daily at
9.00 hrs and 21.00 hrs for 7 days (ICI Dr T. 
Higgin - personal communication).
2.3 Construction of the Perfusion Apparatus
The perfusion apparatus is shown in Figure 2.1 and in 
diagramatic form in Figure 2.2. In the following description 
the numbers in parentheses refer to Figure 2.2.
The main water bath [1] was made of acrylic sheet 0.1
cm thick with the dimensions 40cm by 30cm by 30cm. It was 
heated by a 700 W heater (S.R.I. Edenbridge, Kent) [2] and 
the temperature was maintained at 38.1 °C by a bimetallic 
thermostat C33. Continuous mixing of the heated water by a 
magnetic stirrer [4] ensured uniformity of the water 
temperature within the bath.
Immersed in the bath were two rotating screen 
oxygenators [5,6], (these were a modification of those used 
by Ambec, Beck Industries Inc. U.S.A.). Each consisted of a 
watertight perspex jacket in which a nylon mesh screen 
revolved at 40 rev/min about a stainless steel spindle, which 
in turn was belt driven by an electric motor [7,8], (SRI. 
Cat. no. 116). Each oxygenator was connected via a length 
of polyethylene tubing to a Dale Schuster pump head [9,10].
Each Dale Schuster pump had a variable stroke adjuster 
and was driven at a rate of 145 strokes/rnin by an electric 
motor [11,12]. The dual valve perspex head of each pump 
[13,14] consisted of a central chamber (see Figure 2.3 for 
detail) with movement of the perfusion fluid achieved by the 
reciprocating movement of a fibre re-inforced, rubber 
diaphragm connected to the piston of the pump. The two sets
Figure 2.1 (a,b) - Photographs of perfusion apparatus
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Figure 2.3 - Diagramatic representation of the dual valve pump head
of valves [15,16 and 17,13,], which served as inlets and 
outlets respectively to the chamber, consisted of a neoprene 
ball and guide seated by a stainless steel spring within a 
perspex casing. Each pump outlet valve connected via a 
damping tube of adjustable length [9,20] (which permitted 
fine adjustment of pulse width) and a length of polyethylene 
tubing to the rotary tap [21],
The rotary tap (see Figure 2.4 for detail) consisted 
of two 1 cm thick perspex discs with a polyethylene facing 
locked together but able to rotate around a central bolt. On 
one face of the tap there were two inlets [a,b] receiving 
perfusate from pumps [1] and [2] respectively and two outlets 
[c,d] returning perfusate to oxygenators [1] and [2] 
respectively. On the other face was a Luer outlet [35] which 
connected directly with the aortic cannula of the 
preparation. The Luer fitting also connected to a mercury 
manometer [22] and a Statham-type pressure transducer [23] 
(Model 4.81 Mk 2, S.E. Laboratories) and a thermister [24] 
(a solid glass bead N.T.C. thermister type U.23) which was 
connected to an electronic temperature meter.
The glass chamber containing the excised pancreatic 
block [25] allowed perifusion of the tissue with 
physiological saline (heated to 38.1 °C using the heat 
exchange coil [26]). Circulation was maintained using two 
peristaltic pumps [27,28] set at 5 mls/min.
A flow through oxygen electrode [30] (A modification 
of the PO^ electrode of the blood gas analyzer, Model 48C, 
EIL Ltd.) led into a drop counter [31] with a photoelectric
To Oxygenators.
From Pumps
Position 0
O  B
Position 2 Postion 1
B O
To Pancreas
Figure 2.4 - Diagramatic representation of the double rotary tap
Arrows indicate direction of perfusate flow 
(B - basal S - stimulatory)
drop recorder.
A Technicon Autoanalyzer Sampler (Series 2) [32] was
used to collect the output in plastic 1.5 ml capped 
microcentrifuge tubes. The collection period for each sample 
was 1 minute. An Electro-Medical Multi-channel Amplifier 
[33] (EMMA, SE4001, SE Labs Ltd.) together with an 
ultraviolet recorder (SE 3006, SE Labs Ltd.) were used to 
record the outputs from:
1) Pressure transducer.
2) Temperature display on electronic temperature 
meter.
3) Partial pressure of oxygen from the meter of the 
Blood Gas Analyzer.
4) Drop interval displayed on the electronic drop 
recorder.
A grade A mercury-in-glass thermometer (34) was used 
to calibrate the thermister and temperature meter. All
connecting tubes used in the circuit had an internal diameter 
of 1.3 mm.
2.3.1 Pressure Adjustments
The two pumps were designed to produce a pulsatile 
flow of perfusion medium through the pancreas. It was 
important to be able to control both the amplitude and the 
shape of the pressure pulse created by each pump so as to be 
able to match them exactly. This was possible though 
adjustment of spring tension on both inlet and outlet valves 
which controlled both the volume of fluid ejected per stoke 
and the shape of the pulse. It was essential to balance the 
tension in these springs in order to maintain stable 
perfusion pressures during experiments. Fine adjustments to 
pulse amplitude and shape were achieved by adjustments in the 
length of the damping tube connected to the output of each 
pump head.
2.4 Perfusion Media
A perfusion medium must meet certain requirements in 
order to achieve normal function of an organ in vitro. Thus 
in order to maintain a situation as near as possible to the 
state existing in vivo, an optimum medium must possess the 
following:
1) Sufficient oxygen carrying capacity.
2) An adequately buffered physiological pH, usually
7.4 ie - arterial pH.
3) A physiological concentration of the principal 
ions.
4) A sufficient colloidal osmotic pressure to 
balance the hydrostatic and tissue pressures.
The perfusion medium chosen for this investigation was 
Krebs Henseleit bicarbonate medium as described by Ross 
(1972) and used by many researchers with various additions 
(Curry, Bennett and Grodsky 1968 and Sussman et al 1966), 
containing a final concentration of; NaCl 119 mM, KC1 4.7 
mM, CaCl2 2.5 mM, KHgPC^ 1.2 mM, MgS04.7H20 1.2 mM and NaHCC>3 
25.0 mM.
A stock solution was prepared containing; NaCl, KC1, 
KH2P04 and MgS04.7H20 at a concentration 10 times that of the 
final concentration. This was stored at 4 C for up to 1 
month. On the day of use a 1:10 dilution was made, the CaCl2 
andNaHCO^being added immediately prior to making up the 
solution up to volume with double distilled water. To this 
solution the following reagents were added;
I) Dextran T 70 (Sigma, clinical grade, Mwt. range 
60,000-90,000). Final concentration - 5g/100 mis 
for maintenance of the colloidal osmotic pressure.
II) Bovine Serum Albumin (Sigma, Fraction V, 96—99% 
albumin). Final concentration - 0.25/100mls for 
maintenance of colloidal osmotic pressure and to 
reduce glucagon adhesion to tubing.
III) Adenosine (Sigma, Mwt. 267.2). Final 
concentration - 1.5 mM/1, which maintains the
integrity of the endothelial cells and acts as a 
vasodilator (Davis and Mepham 1974; Baroody 1979).
IV) Glucose Final concentration - 0.72g/100mls 
(4mM). Glucose was included in both basal and 
stimulatory media.
V) Arginine (Sigma, L-Arginine hydrochloride).
Final concentration in stimulatory medium - 10mM.
VI) Trypsin inhibitor (Sigma, Lyophilised from soya 
bean, Type 1-S). Final concentration - 0.1g/1 to 
reduce proteolytic breakdown of glucagon.
vll) Noradrenaline bitartrate (Levophed, Winthrop 
Laboratories). Final concentration - 20, 40, 80 or 
100 ng/100mls of perfusate (Baroody 1979). Used in 
the noradrenaline dose-response studies when it was 
added to both basal and stimulatory media.
The basal and the stimulatory perfusion media were put 
separately into the the two screen oxygenators and were 
oxygenated by a gas mixture (02:C02, 95%:5%) for 30 mins
prior to start of perfusion. Thus at time of perfusion, the 
medium was heated to 38.1 °C, the pH was 7.4 + 0.02 and both 
solutions were saturated with the gas mixture. When 
perfusing with noradrenaline, the procedure for the 
preparation of perfusion media was altered. In order to
ensure minimal breakdown of the noradrenaline prior to or 
during perfusion, the medium (without arginine) was heated 
and oxygenated in a third screen oxygenator for 30 mins. The 
noradrenaline was then added to the total volume of medium, 
then arginine added to half that volume and mixed. Basal and 
stimulatory perfusates were then put in oxygenators 1 and 2 
respectively just prior to perfusion. Thus the two media 
were used within 20 minutes of addition of the noradrenaline.
2.5 Preparation and Isolation of the Rat Pancreas for 
Perfusion
Schematic diagrams of the rat dorsal aorta and major 
arteries and the isolated perfused unit are shown in Figure 
2.5. In the following description the numbers in parentheses 
refer to Figure 2.5. A rat was weighed and then 
anaesthetised by intraperitoneal injection with sodium 
pentobarbitone (Nembutal) at a dose of 5.5mg/100g body 
weight. With the rat supine and its limbs extended, a 
midline incision was made through the skin and the abdominal 
wall from the pubis to the manubrium sterni along the linea 
alba. The cut abdominal wall was slightly retracted 
laterally. A cotton wool pad soaked in warm'0.9% saline was 
placed over the abdominal organs to prevent drying. The 
dorsal aorta was located in the lumbar region posterior to 
the renal arteries and was separated from the inferior vena
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Figure 2.5 - Schematic diagrams of (a) the rat dorsal aorta
and major arteries (b) the isolated perfused unit
For ligatures (1-17) refer to text 
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cava and connective tissue rostrally for a short distance 
(approximately 1cm) where a loose ligature [1] was placed. 
By displacing the intestine, the stomach and the spleen to 
the right side of the animal, the dorsal aorta was located 
anterior to the left renal artery where the superior 
mesenteric artery and the coeliac axis branch. The area was 
cleaned of fatty tissue and a loose ligature [2] was placed 
around the aorta between the inferior mesenteric artery and 
the coeliac axis. The superior adrenal artery was located 
and tied by ligature [33. The three branches from the 
coeliac axis, the left gastric artery, the right gastric 
artery and the hepatic artery were located and tied by 3 
ligatures [4], [5] and [6]. Blood vessels of the spleen were 
collected in 3 adjacent groups and tied within 3 ligatures 
C7f8,9]. At this point the oesophagus was also tied to 
isolate the stomach [10].
The abdominal contents were then shifted to the left 
of the animal and the hepatic portal vein and gastrohepatic 
ligament located. Two loose ligatures were placed around the 
major vessels leading into the hepatic portal vein from parts 
of the intestine beyond the duodenum [11,12].
A ligature was placed around the aorta anterior to the 
coeliac axis in the vicinity of the crura of the diaphragm 
[13] and firmly tied, thus occluding the blood supply from 
the heart. Immediately after this a small incision was made 
in the wall of the aorta posterior to ligature [1] and the 
cannula (Portex, nylon intravenous cannula, external diameter 
0.63mm, Luer mount, cut to 15 cm) was introduced rostrally 
inside the aorta, until its tip reached the origin of the
coeliac axis. Ligatures [1] and [2] were then firmly tied 
and 0.1ml (2 IU) of heparin (Heparin, 1000 IU per ml:
diluted 1:50 with nomal saline and heated to 38.1 °C) was
introduced into the cannula, which was then connected to the 
main flow of basal perfusate from the main outlet of the 
rotary tap via an extended cannula (Portex, nylon cannula, 
external diameter 2mm, 80 cm long, Luer connector at both 
ends). Blood was immediately seen to clear from the perfused 
organs.
The hepatic portal vein was then cannulated at a point 
between ligature [14] and the entry of the hepatic portal 
vein into the liver. Because of the fragility of this vessel 
it was found to be easier using a luer-fitted cannula 
(0.01mm) with an introducer. The introducing needle was then 
withdrawn and the tip of the cannula placed approximately 5mm 
inside the portal vein whilst ensuring that the tip was not 
occluded by the vessel wall. Ligatures [14] and [15] were 
tied as were Ligatures [11] and [12]. A further two 
ligatures were placed and tied around the junction to the 
duodenum and the jejunum [15] and [16],and a cut was then 
made between the two ligatures.
The aorta was separated posterior to ligature [1] and 
anterior to ligature [13] and the segment between these two 
points freed of all dorsal attachments. Thus the pancreas, 
the duodenum, the stomach, the spleen, and the aortic segment 
with the arterial cannula were all isolated in one block. 
The whole unit was washed with warm 0.9$ saline solution and 
transferred to the organ chamber in the water bath. The 
cannula was connected to the main outlet of the rotary tap
after removal of the connecting cannula. The entire 
operation took approximately 20 mins with a maximum period of 
1 minute of anoxia during arterial cannulation.
The viability of the isolated perfused pancreatic 
preparation was assessed according to the following criteria:
1) Arterio-venous oxygen differences.
2) Physical appearance of the perfused pancreas and 
peristaltic movements of the duodenum.
3) Increasing vascular resistance (a sign of 
failure of the perfusion).
2.6 Operation of Apparatus During Perfusion
With the main bath heated to 38.1 + 0.1 °C, prior to
commencement of perfusion, the two oxygenators were filled 
with normal saline solution and rotation commenced. The Dale 
Schuster pumps were switched on and the saline solution 
allowed to recirculate within each system before being pumped 
out. 30mls of basal and of stimulatory medium were then 
flushed through the two circulating systems before a further 
200mls of basal and stimulatory medium were put into screen 
oxygenators 1 and 2 respectively. These volumes of media 
partly filled the resevoirs and immersed the lower half of 
the nylon mesh screens. The two oxygenators were connected 
in series to a supply of gas (a 95$:5 %, 0^:C02 mixture)
delivered at a rate of 200 mls/min through a rotameter-type 
gas flow meter.
The pumps were started with the rotary-double tap in 
position (0) (see Figure 2.4), enabling recirculation of each 
perfusate within separate circulatory systems. After 30 mins 
a 80cm long cannula was connected from the main outlet of the 
rotary tap to an inlet of screen oxygenator 1. The 
rotary-double tap was then switched to position (1), thus 
still allowing separate recirculation of both sets of 
perfusion medium, but causing the basal perfusate to be 
redirected via the main outlet of the double tap and the 
extended cannula back to the oxygenator. Thus, when arterial 
cannulation of the pancreas preparation was completed, the 
extended cannula could be joined to the arterial cannula and 
so commence perfusion of the pancreas in situ.
Once the organ block had been isolated, the connecting 
cannula was removed and the preparation quickly transferred 
to the glass organ chamber where the arterial cannula was 
reconnected directly to the main outlet of the rotary-double 
tap. The hepatic portal vein cannula was then connected via 
a Luer-ended polyethylene tube to the oxygen electrode from 
where the flow was directed through the drop counter to 
waste. The preparation was perfused for 15 mins before 
sample collection commenced. The venous effluents were 
collected in 1.5ml capped microcentrifuge tubes containing 50 
ul of 0.24M EDTA in order to minimise breakdown of glucagon 
by pancreatic proteases which are calcium dependent 
(Mandarino, Stenner, Blanchard, Nissen and Gerich 1981). 
Outputs of basal perfusion medium were collected at 1 minute
intervals for 5 minutes. At the end of the fifth minute the 
rotary-double tap was switched to position (2), thus 
commencing perfusion with the stimulatory medium.
Throughout the experiment the perfusion pressure was 
kept at 7 4 + 8  mmHg depending on the flow resistance of each 
preparation. Arteriovenous (ie output-input) oxygen tension 
differences ranged between 240 mmHg and 260 mmHg. The 
perfusate "arterial” (input) oxygen tension after 
equilibratioin with O^rC^ (95%:5%) ranged between 345 and 
365 mmHg (Mean + S.E.M.- 360 mmHg + 2.6), whilst the "venous" 
(output) oxygen tension was 106 + 2.3 mmHg. In accordance 
with studies by Holst, Jensen, Nielson and Schwartz (1980), 
this allowed adequate provision of oxygen to the isolated 
perfused pancreas.
The samples were removed from the fraction collector 
and kept in an ice bath until the end of the experiment. 
They were then transferred to and maintained at -20 °C. At
the end of each perfusion, a solution of 10$ (w/v) methylene 
blue in 0.9$ NaCl was infused via the arterial cannula. 
Stained pancreatic tissue lying within the duodenal 
mesentery, the gastrosplenic ligament and along the hepatic
portal vein was carefully dissected out under 15X
magnification, the tissue was blot-dried and weighed to 
obtain pancreatic wet weight. It was then dried at 104 °C for 
48 hours before reweighing to obtain dry pancreatic weight.
In order to obtain evidence of the degree to which 
cold acclimation had occurred, in every case the
interscapular fat pad was removed and the brown adipose
tissue (BAT) carefully dissected free of adherent white 
adipose tissue and skeletal muscle. The BAT wet weight was 
then determined.
Cleaning of the apparatus - Because of the rapidity of 
bacterial growth within the perfusion medium, it was 
essential to clean the apparatus thoroughly after each set of 
perfusions. Therefore each day the whole apparatus was 
disassembled and washed with detergent. It was then 
carefully rinsed with tap water 3 times and then twice with 
double-distilled deionised water before being left to dry.
3 GLUCAGON RADIOIMMUNOASSAY - MATERIALS AMD METHODS
3.1 Introduction
Unger and coworkers (1968) applied the principles of 
radioimmunoassay to the measurement of glucagon in blood 
after Yalow and Berson (1959) first introduced the technique 
for measuring plasma insulin. During the past 20 years, a 
great deal of work has been devoted to improving the glucagon 
radioimmunoassay (Samols, Tyler Meggesi and Marks 1966; 
Nonaka and Foa 1969; Heding 1971; Luyckx 1972 and Alford, 
Bloom, and Nabarro 1977). A number of artifacts and 
interfering factors have been detected, the sensitivity has 
been markedly improved and important progress has been made 
in the area of specificity.
The glucagon assay protocol used in this study is 
essentially that developed by A1 Tamar (1978) and Tsiolakis 
(1979) and is based on that of Buchanan and McCarroll (1971). 
- Extraction to reduce interference with plasma proteins was 
unnecessary as a synthetic perfusion medium was used for the 
perfusion experiments (as described in section 2.3).
It has been recognised for some time that labelled 
pancreatic glucagon was susceptible to enzymatic breakdown
which could be reduced by the addition of aprotinin
(Trasylol) a proteinase inhibitor (Eisentraut, Whissen and
Unger 1968). Since then, Trasylol has been routinely used in
glucagon radioimmunossay. In addition to Trasylol which is a 
polypeptide derived from beef parotid glands, another 
proteinase inhibitor, trypsin inhibitor derived from 
soyabean, has also been used.
3.1.1 Materials
I) Assay buffer - A 0.04M stock phosphate buffer (pH 
7.4) was prepared and stored for up to one month at 4 °C. 
Double distilled water was used in the preparation of all 
reagents. The assay buffer was made up fresh each day by
adding 2% heat inactivated horse serum no. 5 (Wellcome 
reagents Ltd., Beckenham, Kent) and 100ug/ml aprotinin
(Sigma, Bovine Lung Protease Inhibitor 26 TIU/ml) to the 
stock phosphate buffer. This buffer was then used in the 
assay tubes and for dilution of both antiserum and label.
II) Standards - The WHO 1st International Standard for 
Glucagon (porcine) for Bioassay (69/194) obtained from the 
MRC National Institute for Biological Standards and Control, 
London, was used. Each ampoule contained 1.49 I.U. of 
porcine glucagon (N.B. Each glucagon International Unit is 
approximately equal to 1mg). The contents of each ampoule 
were dissolved in acid-ethanol (1.5 mis cone HC1:75 mls 
absolute ethanol:25mls water) to give a stock solution of
100pg/inl. This stock standard was aliquotted into 0.5 ml
volumes and stored at -20 °C. This stock was then diluted 
with the same acid-ethanol mixture to give a Working Standard
of 1pg/ml which was again aliquotted and stored at -20 °C. 
Stored in this manner it was stable for up to four months. 
To prepare the Standard Curve, 10pl of the Working Standard 
(1pg/ml) was added to 3.99 mis of assay buffer. This was the 
top assay standard of 2500 pg/ml, further standards 1250 
pg/ml, 625 pg/ml, 312 pg/ml, 156 pg/ml, and 78 pg/ml were 
produced by serial double dilutions with assay buffer. 100pl 
of standard was added to the assay standard tubes.
III) Quality controls - Quantities of the perfusion 
output from the isolated perfused pancreas were spiked with 3 
different concentrations of glucagon standard (covering the 
top and bottom range of the standard curve), which were then 
aliquotted into 0.5ml volumes and stored at -20°C.
IV) Sample buffer - 5ml volumes of perfusion medium 
were aliquotted and stored at -20 °C for use as the sample 
buffer in the assay.
125V) I-Labelled glucagon - This was prepared by the 
classical method of Hunter and Greenwood (1962) using a 
chloramine-T iodination. A method of ion-exchange 
chromatographic purification with QAE Sephadex (Hunter and 
Greenwood 1962) was used to purify the iodinated hormone. 
See Figure 3.1 for Iodination profile. The peak fractions 
from the eluate passed through the ion exchange column were 
pooled and diluted 1:1 with an acid-ethanol solution and 
stored at -20 °C. 100 pi of diluted label was added to the
assay so that each tube contained appromimately 10,000 
counts/100 seconds (approximately 15 pg).
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VI) Glucagon antiserum - Babbit anti-pancreatic 
glucagon serum (Batch MF/R/4-LB) directed against an 
immuno-determinant in the carboxyl terminal region of the 
glucagon molecule (residues 24-29) was used. It was obtained 
from Guildhay Antisera, Guildford, and stored at 1/100 
dilution with 0.04M phosphate buffer at 4€. Antiserum 
dilution curves were constructed by incubating a constant 
amount of label (approximately 15 pg) with double-diluted 
concentrations of antiserum for 24 hrs at 4 °C and were used 
to determine the working antiserum titre for use with the new 
label (see Figure 3.2). The working antiserum titre was 
defined as the concentration of antiserum that gave 50% 
maximum binding of the label; this was calculated to be 
1/15,000. This final dilution was made with assay buffer on 
the day of use. 100 pi of the 1/150000 dilution was added to 
all standard and unknown tubes. Cross reaction studies to 
evaluate the specificity of the MF/R/4-LB antiserum (Tan 
1982) failed to show any interference with secretin, but gave 
a cross-reaction with porcine gut GLI of 1% up to 8ng/ml .
VII) Dextran coated charcoal - A 1% charcoal 
suspension was prepared by mixing 5g of charcoal and 0.5g 
Dextran T-250 (Pharmacia) with 500mls of stock phosphate 
buffer, this was prepared 24 hrs before use and stored at 4 
°C. For use in the assay, 100pl of the charcoal suspension 
was added to each tube to give a final concentration of 
0.15%. After addition of the charcoal, the tubes were 
allowed to stand for 10 mins before centrifugation at 1,500 x 
g for 20 mins.
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3.1,2 Methods
I) Protocol
The following tables indicated assay design and 
protocol:
TUBE CODE CONTENTS TUBE NOS
TC TOTAL COUNTS 4
NSB NON SPECIFIC BINDING 4
0 ZERO 4
STD 1 78 (pg/ml) 4
STD 2 156 (pg/ml) 3
STD 3 312 (pg/ml) 3
STD 4 625 (pg/ml) 3
STD 5 12500 (pg/ml) 3
STD 6 2500 (pg/ml) 3
QC 1 QUALITY CONTROL 2
QC 2 QUALITY CONTROL 2
QC 3 QUALITY CONTROL 2
UK 1-50 SAMPLE 2
Table 3.1 - Glucagon RIA Design
TUBE ASSAY SAMPLE STD/UK A/S LABEL
BUFFER BUFFER
Vol (pi) Vol (pi) Vol (pi) Vol. (pi) Vol (pi)
TC . . . . . . 100
NSB 200 100 ----- ----- 100
0 100 100 ----- 100 100
STD ---- 100 100 100 100
UK/QC 100 ----- 100 100 100
Table 3.2 - Glucagon RIA Protocol
PROCEDURE
DAY ONE Addition of 
Buffer 
Std/QC/UK 
A/S
Incubate at 4 °C for 24 hrs
DAY TWO Addition of label 
Incubate at 4 °C for 48 hrs
DAY FOUR Addition of charcoal 
Incubate 20 min 
Spin at 1,500 g for 20 mins at 4 °C 
Aspirate supernatent 
Count charcol pellet
II) Assay precision and sensitivity
Quality Controls - Using four sets of quality controls 
in triplicate for each standard curve over 12 sets of 
standard curves, the interassay coefficient of variation was 
calculated to be 20%. The mean coefficient of variation 
within assays ie - intra-assay variation was 12%. Current 
radioimmunoassays for plasma pancreatic glucagon are
unreliable (Heding et al 1971; Luyckx 1972) due to 
quantitative interference by non-specific factors known to be 
present in plasma (Heding et al 1971; Unger and Eisentraut 
1968 and Weir 1975), the reason for such large inter-assay 
variation within this study in which the assay was used to 
estimate glucagon concentrations from samples of synthetic 
perfusion medium is unclear, but may be due to the necessary 
presence of bovine serum albumin in the medium.
Standard Curve - Under conditions described for the
radioimmunoassay of glucagon, increasing quantities of
125unlabelled glucagon displaced I-glucagon in the range of
78-2500 pg (see Figure 3.3). The sensitivity of the assay, 
defined in terms of the slope of the dose response curve - ie 
the change in the response parameter for a given change in 
the dose (2 standard deviations), is equal to 78 pg/ml. 
Non-specific binding (NSB) varied with the age of the tracer 
but was never greater than 6%.
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Figure 3.3 - Glucagon radioimmunoassay standard curve
(Values are Mean ±S.E.M„ n = 9)
4 ACQUISITION AND PROCESSING OF DATA
4.1 Normalisation of Data
As seen in chapter 2, the quality controls indicated 
high interassay and intrassay variation (12% and 20% 
respectively). In order to reduce the effects of this 
variation on the data, all samples were normalised to a mean 
set of quality controls (calculated using all 25 groups of 
quality controls). Each set of quality controls and the 25 
samples assayed with them were adjusted so that all the 
quality controls were of the same value as the standard 
quality controls. Thus all glucagon data was normalised to 
negate any artifactual effects produced by high coefficients 
of variation.
In order to obtain glucagon secretion rates, thus 
providing estimates of total glucagon secretion during each 
one minute sample, the glucagon concentration was multiplied 
by the flow rate of each one minute collection period 
(ie-volume of each sample, estimated by weight assuming a 
specific gravity of 1.000 g/inl for the Krebs Ringer). Oneway 
analysis of variance showed no significant differences 
between flow rates for each experimental group.
Statistical analysis showed a significant positive 
correlation between pancreatic weight and mean glucagon 
output (r<0.1442, p<0.00005). Correction of glucagon
concentration by pancreatic weight, to produce estimates of 
glucagon secretion per unit mass of pancreas (ng 
glucagon/min/g dry wt pancreas) was therefore justified. Dry 
pancreatic weight was used to avoid any anomalous effects 
which might be produced by oedema (although no pancreata 
which were obviously oedematous were included in the 
results). Brown fat weights were estimated as described in 
chapter 3. Both dry pancreatic weights and BAT weights were 
adjusted by rat body weight to give tissue weights as mg of 
tissue /100g body weight, thus negating the effects of 
variations in body weight.
Comparison of body weights, pancreatic weights and BAT 
weights between experimental animal groups was made using 
oneway analysis of variance and followed, where appropriate, 
by Duncan's Multiple Range Tests (alpha = 0.05).
4.2 Statistical Analysis of Glucagon Secretion Profiles
The glucagon secretion data was assessed a priori by 
means of a multivariate repeated measures design of analysis 
of variance, providing a two-way anlysis of group, time and 
group-time interactive effects. This was carried out using 
all groups within an experiment, to establish an effect of 
the independent variable under investigation (ie- cold 
exposure period, noradrenaline dose or adrenergic blockade). 
Analysis was done using all 25 time points within the 
secretion profiles. Repeated measures design also gave 
indications of significant effects of time and dose-time
interactions, indicating any effects of time within the 
secretion profile, whilst dose-time interactions indicated 
the degree of non parallelism between the secretion profiles. 
If a significant effect of group and time was established, 
analysis of mean secretion rates calculated over the whole 
secretion profile and for individual time phases was carried 
out using oneway analysis of variance and followed, where 
appropriate, by Duncan’s multiple range test (alpha = 0.05)
to establish homogenous subgroups within each experimental 
procedure. Duncan’s Multiple Range Test was used in order to 
avoid the spurious significant results potentially generated 
by multiple comparisons using Student’s t-tests.
Thus comparison of mean glucagon secretion rates was 
made using;
1) Total glucagon secretion period (1-25 min).
2) Basal glucagon secretion (1-5 min).
3) Arginine-stimulated glucagon secretion-Phase 1 (6-7 min).
4) Arginine-stimulated glucagon secretion-Phase 2 (9-25 min).
The experiments and results are considered in the 
following three chapters and discussed immediately after 
presentation of the data. The general discussion, which then 
follows, attempts to link and inter-relate the separate 
findings reported.
5 THE TIME COURSE EFFECTS OF CHRONIC COLD EXPOSURE
5.1 Introduction
There is much evidence to suggest an effect of cold 
exposure on basal plasma glucagon levels. Both hypothermia 
(Helman et al 1984) and acute cold exposure (Seitz et al 
1981; Takahashi et al 1984; Kuroshima, Yahata and Ohno 
1981; Sasaki et al 1982) have been shown to elevate plasma 
glucagon levels, whilst studies by Kuroshima and Doi (1976) 
and Kuroshima et al (1978) on the effects of chronic cold 
exposure have demonstrated an increase in basal plasma 
glucagon after 2 weeks cold exposure in the rat, followed by 
a return to control values after 4 weeks cold exposure. Thus 
the purpose of this set of experiments was; 1) to 
investigate the time course effects of chronic cold exposure 
on basal and arginine-stimulated glucagon secretion from the 
isolated perfused pancreas and so to identify any progressive 
changes in secretion during the process of cold acclimation, 
and 2) to monitor the associated changes in insulin 
secretion, thereby enabling an assessment of the net effect 
of continued cold exposure on the insulin:glucagon molar 
ratio of the pancreatic effluent.
5.2 Glucagon Secretion
5.2.1 Methods
In order to investigate time course changes in 
glucagon secretion patterns at low temperature the pancreata 
from groups of warm acclimated, cold 2, cold 4 and cold 6 
rats were perfused as described. Repeated measures two way 
analysis of variance of glucagon secretion rates using all 
four experimental groups (warm acclimated, cold 2, Cold 4 and 
Cold 6 groups) was carried out using all 25 time points of 
the secretion profile to identify significant effects of;
1) Environmental temperature and duration of
cold exposure.
2) Time effects within the perfusion profile.
3) Environment-time interaction.
In order to clarify and quantify the effects of cold 
exposure and its duration, where significant effects were 
established a oneway analysis of variance followed, where 
approporiate, by Duncan’s multiple range test (alpha = 0.05) 
was carried out using mean secretion rates calculated for 
total perfusion period and for individual secretion phases.
5.2.2 Results
Mean body weights, BAT . weights and dry pancreatic 
weights (mg/100g body weight) for each animal group are given 
in Table 5.1. A significant increase in mean body weight was 
seen after 6 weeks cold exposure (P<0.05). BAT weights 
showed a significant increase after 4 and 6 weeks cold 
exposure to values (124.6%) and (138.9%), respectively, of 
warm control BAT weights (P<0.05). Cold exposure had no 
effect on pancreatic weight.
COLD
EXPOSURE
(wks)
RAT
WEIGHT
(g)
DRY PANCREATIC 
WEIGHT 
(mg/100g)
BROWN FAT 
WEIGHT 
(mg/100g)
MEAN SEM MEAN SEM MEAN SEM
0 308.5 + 6.8 96.9+ 9.2 144.1 + 16.1
2 308.7 + 6.1 98.3 + 5 . 4 140.3 + 10.3
4 306.2 + 9.2 90.8 + 5.0 179.5 + 11.5
6 348.3 + 8.6 102.3 + 6.2 200.1 + 22.8
Table 5.1 - Body and tissue weights of animal groups 
subjected to 0, 2, 4 and 6 weeks cold exposure.
The glucagon secretion profiles for each group are
presented in Appendix 1 (A. 1 - A.4) and graphically in Figure 
5.1. Repeated measures two-way analysis of variance shows a 
significant effect of cold environment, perfusion time and 
cold-time interaction as indicated in table 5.2.
p<
COLD EFFECT 0.0050
TIME EFFECT 0.0010
COLD/TIME INTERACTION 0.0010
Table 5.2 - Repeated measures two way analysis variance 
showing the effects of cold exposure, time and cold-time 
interaction on the glucagon secretion profile.
Oneway analysis of mean secretion rates, followed by 
Duncan’s Multiple Range Test, is summarised in Table 5.3 and 
in Figure 5.2.
Tne mean secretion rate for the total 25 minute 
perfusion period was significantly elevated after two and 
four weeks exposure relative to both the warm acclimated 
control group and the six weeks cold exposed group, reaching 
values 195% and 179% of the warm control group respectively. 
No significant differences were observed between the warm 
control group and the six weeks cold exposed group.
Basal secretion was significantly reduced in the 6 
weeks cold exposed compared to the warm control group.
Mean phase 1 secretion rates were elevated after two 
and four weeks cold exposure to values 496% and 331% of the 
warm acclimated control group respectively. Phase 1 
secretion rates for the two weeks cold exposed group were 
also significantly greater, than values for both four and six 
weeks cold exposed groups. Again no significant change was 
observed after six weeks cold exposure when compared to the 
warm control group.
Mean phase 2 secretion rates of both two and four 
weeks cold exposed groups were not significantly different 
from warm control values although both were significantly 
greater than the six weeks cold exposed group. The warm 
acclimated group and 6 weeks cold acclimated group are used 
as the warm acclimated control and cold acclimated control in 
subsequent experiments.
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5.3 Insulin:Glucagon Molar Ratios
5.3.1 Methods
A set of 6 pancreatic perfusion effluents for warm 
acclimated, Cold 2, Cold 4, and Cold 6 groups were assayed 
for insulin in this laboratory using a Sephadex-adsorbed 
antibody radioimmunoassy method (Phadebas Insulin Test - 
Pharmacia Diagnostics against rat insulin standards) and 
compared with the glucagon data for the same perfusions. 
Total insulin and glucagon outputs for each of the four 
groups were obtained by integrating the area under each 
secretion profile, and using this data, the insulin:glucagon 
molar ratios were calculated. Total hormonal outputs and the 
insulin:glucagon molar ratios for each test group were then 
compared to the control group using Students t-test for 
unpaired data as reported (Edwards and Howland 1986).
5.3.2 Results
Insulin - Figure 5.3 shows a continuing reduction in 
total insulin output associated with increased duration of 
exposure to 4 °C. At 2 weeks of exposure a tendency towards 
reduced total insulin was evident. At 4 weeks, total output 
was 61% of that of warm control group (p<0.002), while at 6 
weeks cold exposure total output was 45% of that of the warm
Figure 5.3 Upper - Insulin:Glucagon molar ratios with
progressive cold exposure
Lower - Histogram of insulin and glucagon total 
outputs with progressive cold exposure
Open colums indicate insulin outputs; stippled columns indicate glucagon 
outputs.
Statistical significances: *P<0.05, **P<0.02, ***P<Q.Q1 and 
****p<0.0001 aii with respect to warm control data by Student’s 
t test.
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acclimated group (p<0.0001).
Glucagon - Total glucagon outputs of the perfusate 
samples measured showed significant increases at 2 and 4 
weeks exposure to 4 C. Thus at 2 weeks exposure, total 
output is increased by 165% (p<0.05) and at 4 weeks by 128% 
(p<0.02). At 6 weeks, total glucagon output returned to
levels of the warm control group.
Insulin:Glucagon Molar Ratios - In all cases the molar 
ratio of the outputs from the 4 °C exposed groups was
substantially reduced to 29% (p<0.05), 20% (p<0.01) and 18%
(p<0.0001) of control group value at 2, 4 and 6 weeks
respectively. Thus, a sustained reduction of some 70% in 
insulin:glucagon molar ratios was evident at all durations of 
cold exposure.
5.4 Discussion
5.4.1 Arginine-Stimulated Glucagon Release
The biphasic release of glucagon in response to 
arginine seen in this study is in good agreement with other 
in vitro work using the isolated perfused pancreas (Gerich et 
al 1974a, 1976a; Pek 1976). Dose-resonse studies by Gerich 
et al (1974a) suggest that a 10 mM arginine stimulation would 
result in maximal stimulation of the A cell. The suppressive
effect of glucose on the A cell response to arginine is well 
documented (Gerich et al 1974a), but the literature suggests 
that 4.4 mM glucose as used in the present study would have 
only a minor moderating influence. The mechanisms of 
arginine-stimulated glucagon release have not, as yet been 
elucidated. It is known to be a calcium dependent process
(Leclercq- Meyer, Marchand and Malaisse 1976) and there is
some evidence that a cell membrane receptor is involved 
(Assan et al 1977). It does not appear to involve cAMP, as 
demonstrated recently by Pipeleers et al (1985b), although 
there is evidence of modulation of the arginine stimulus by 
hormone induced cAMP signals; ie insulin, catecholamines and 
somatostatin (Pipeleers et al 1985b; Jarrousse and Rosselin 
1975).
The biphasic secretory response of the A cell to 
arginine markedly resembles the biphasic insulin secretory 
response to glucose. However, whilst much work has been done 
on the secretory mechanisms of biphasic insulin release 
(O’Connor, Landhal and Grodsky 1980), little is known about 
the mechanisms of the biphasic glucagon profile. Similarly, 
the contribution of de novo synthesis to the biphasic
glucagon response is unknown. Certainly in the case of
insulin secretion, there is evidence to indicate that glucose 
promotes the release of newly synthesised hormone as 
indicated by Howell, Parry and Taylor (1965) using incubated 
rabbit pancreatic slices. Investigations into the dynamics 
of insulin secretion (Curry et al (1968) suggested an 
involvement of such newly synthesised insulin release in 
phase 2 of the secretory response to glucose. However, time 
course studies by Sando and Grodsky (1973) using perifused
rat islets indicated that newly synthesised insulin release 
did not contribute to the first or second phase of the 
secretory respose observed within the first hour of glucose 
stimulation. This is further supported by Sorenson, Steffes 
and Linsall (1970) who were able to estimate a total 
conversion time for proinsulin to insulin as just under one 
hour.
Thus if similar secretion mechanisms are responsible 
for glucagon release, it is unlikely that de novo synthesis 
represents a significant fraction of the biphasic secretory 
response observed within 20 minutes of arginine-stimulation.
5.4.2 Cold-Induced Changes in BAT
The data indicates a significant effect of low 
environmental temperature on BAT weight (mg/100g body 
weight), showing a 120% and 138% increase in BAT weight over 
warm control values after 4 and 6 weeks cold exposure 
respectively. This is in agreement with other workers who 
have found similar increases after cold exposure for a period 
of 3-4 weeks (Senault et al 1981; Desautels et al 1978;
Thompson et al 1969). Indeed it has been suggested that
assessment of the adaptive status of the cold exposed animal 
can be made by monitoring changes in BAT weight (Bukowiecki 
et al 1982). Thus the data indicates that the animal groups
used in this study are fully acclimated after a period of 4
weeks exposure to cold. Table 5.1 also indicates a 
significant effect of cold exposure on body weight, with a
significant increase in body weight after 6 weeks cold 
exposure. This is in disagreement with other studies which 
have reported a reduced body weight gain during cold
acclimation despite increased food intake (Harada, Habara, 
and Kanno 1982), although such a finding is not without 
exception (Vallerand, Lupien and Bukowiecki 1983).
5.4.3 Cold-Induced Changes in Glucagon Secretion
Basal plasma glucagon concentrations have been shown 
to rise in response to acute cold exposure in man and in the 
rat (Seitz et al 1981), and in response to chronic cold
exposure (two weeks) in the rat (Kuroshima and Doi 1976; 
Kuroshima et al 1978). Elevations in both basal and 
arginine-stimulated glucagon concentrations have been 
demonstrated in response to hypothermia in the rat (Helman et 
al 1984), short term cold exposures in the calf and piglet 
(Takahashi et al 1984, Takahashi 1984) and chronic cold 
exposure in the sheep (Sasaki et al 1982). The data in this
study showing an enhancement of both first and second phases
of arginine stimulated secretion in cold 2 and cold 4 animals 
similarly indicates significant stimulatory effects of prior 
cold exposure on glucagon release using the isolated perfused 
pancreas.
That cold exposure causes a considerable increase in 
sympathetic activity (Picotti et al 1981; Young et al 1982; 
Benedict et al 1977a; Leduc 1961), resulting particularly in 
increased noradrenaline turnover rates in the pancreas (Young
and Landsberg 1979) is well documented. An increase in 
glucagon secretion in response to sympathetic stimulation has 
also been extensively reported, with electrical stimulation 
of the sympathetic innervation to the pancreas, 
stress-induced increases in sympathetic activity and in vivo 
and in vitro stimulation with exogenous noradrenaline, all 
resulting in increased plasma glucagon levels and 
concomittant inhibition of insulin release (Bloom and Edwards 
1978; Bloom et al 1978; Andersson et al 1982; Kaneto et al 
1975b; Bobbioni et al 1983). In view of this it is
reasonable to suggest that in the present study the increase 
in glucagon secretion is the result of a stimulatory effect 
of an increased sympathetic activity acting upon the pancreas 
in vivo.
However the mechansisrns by which increased sympathetic 
stimulation in vivo can result in increased
arginine-stimulated glucagon release in the isolated perfused 
pancreas in the absence of any central nervous control is
unclear. It is suggested that the effects could be
attributed to any or all of the following:
1) Enhanced sensitivity of the A cell to 
arginine stimulation. Concomittant stimulation of the A cell 
with arginine and adrenaline/noradrenaline results in an 
amplification of the arginine stimulus (Pipeleers et al 
1985b; Beard, Weinberg, Pfeifer, Best, Halter and Porte 
1983). There is also evidence of an intrinsic nerve supply 
within the pancreas (Hontin 1956) which remains intact in the 
isolated perfused pancreatic preparation providing a 
functional intrapancreatic adrenergic mechanism which 
operates to control glucagon secretion (Hisatomi et al 1985).
Since Young and Landsberg (1979) have demonstrated a 
cold-induced increase in pancreatic noradrenaline turnover it 
is possible that elevations in intrinsic sympathetic activity 
within the isolated perfused pancreas are involved in 
determining the enhanced A cell response to arginine seen 
after 2 and 4 weeks cold exposure.
2) An increase in the amount of stored hormone. If 
the assumption is made that, like insulin (Sando and Grodsky 
1973), the initial biphasic glucagon secretion represents the 
release of stored and not newly synthesised glucagon, then an 
enhanced secretion in response to arginine stimulation could 
imply an increase in the amount of stored glucagon within the 
isolated pancreas. This could be indicative of an increased 
hormone synthesis in response to chronic sympathetic 
stimulation in vivo.
One or both of the above mechanisms could also be 
responsible for the continued decrease in insulin release 
from the isolated perfused pancreas in response to continued 
cold exposure, which in turn could, through the removal of 
its inhibitory influence on the A cell (Ostensen 1979) also 
contribute to the enhanced release of glucagon.
After six weeks cold exposure a significant fall in 
basal glucagon secretion and the disappearance of the 
enhanced arginine-stimulated glucagon release is observed. 
This is consistent with a report by Kuroshima et al (1978) 
who observed changes in the glucagon concentration of mixed 
trunk blood paralleling those reported here, although it must 
be noted that return of glucagon levels to control values in
his study was observed after four not six weeks. These 
changes in glucagon secretion with prolonged cold exposure 
are seen despite a progressive and continuing reduction in 
insulin levels as seen in this study, as well as evidence 
from other studies of maintained elevated plasma 
noradrenaline levels which, whilst they appear to fall after 
four weeks are still 2-4 times control values (Le Blanc and 
Nadeau 1961). Thus further changes must occur with continued 
cold exposure, to account for these alterations in glucagon 
secretion.
Many studies have indicated changes in adrenergic 
receptor number and sensitivity with continued adrenergic 
stimulation. There is certainly evidence of down-regulation 
of BAT beta receptors during chronic cold exposure 
(Buckowieki et al 1978; Nedergaard 1982) although other 
workers have also demonstrated a concomittant upregulation of 
alpha receptors (Raasmaja, Mohell and Nedergaard 1984). It 
may at this stage be postulated that the abolition of the 
enhanced A cell response to arginine after 6 weeks cold 
exposure results from a desensitisation of the A cell to cold 
induced sympathetic stimulation possibly, through changes in 
adrenergic receptor sensitivity or number. This possibility 
will later be considered in more detail.
5.4.4 Cold-Induced Changes in Inulin:Glucagon Molar Ratios
In vitro studies using rat white adipose tissue have 
indicated that an insulin:glucagon molar ratio of 0.2 or less 
is required before lipolysis occurrs in vitro (Lefebvre 1969, 
as cited by Lefebvre 1975), although an insulin:glucagon 
molar ratio as low as this is rarely observed under 
physiological conditions and is certainly much lower that the 
values obtained in this study. However, Lefebvre (1975) has 
since suggested that numerous other lipolytic hormones are 
also likely to contribute to a net lipolytic effect in vivo 
and should therefore also be taken into consideration. Unger 
(1971) has suggested that the molar ratio of these two 
hormones probably still provides a truer indication of net 
biological activity of the islets in terms of rate and 
direction of metabolic fuel fluxes than examination of 
individual hormone concentrations in the blood. This study 
shows a significant drop in insulin:glucagon molar ratios at 
2 weeks cold exposure which is similarly maintained for the 
whole 6 weeks of the cold exposure period under 
investigation. This is indicative of a marked shift in the 
balance between catabolic and anabolic processes to a 
predominantly catabolic state.
6 NORADRENALINE DOSE RESPONSE EFFECTS IN THE WARM AND COLD
6.1 Introduction
Despite demonstrations of down regulation of beta 
adrenoceptors in certain tissues of the cold acclimated 
animal (Buckowiecki et al 1978) there is conversely much 
evidence for an enhanced sensitivity of the cold acclimated 
animal to noradrenaline as indicated by increased thermogenic 
responsiveness (Foster et al 1980; Fregly et al 1977; 
Evonuk and Hannon 1963; Barney et al 1980) and 
cardiovascular responsiveness (Foster et al 1980; Evonuk ej: 
al 1963). Thus in order to elucidate further the A cell 
response to adrenergic stimulation in the cold acclimated 
animal,' a second set of experiments were performed to 
investigate the effects of differing doses of noradrenaline 
in the perfusion media on glucagon secretion from the 
isolated perfused pancreas of both warm and cold acclimated 
rats.
6.2 Methods
Five doses of noradrenaline within the perfusion 
medium were used (0, 20, 40, 30 and 100ng/100mls). A set of 
perfusions were performed at each dose using both warm 
acclimated animals and cold acclimated animals. The
perfusions were carried out and the venous effluents were 
assayed for glucagon using the materials and methods 
described in Chapters 2 and 3.
For both warm and cold noradrenaline data, repeated 
measures two way analysis of variance of glucagon secretion 
profiles using all five noradrenaline doses was carried out, 
as previously described, to indicate the significant effects 
of:
1) Noradrenaline dose.
2) Time effects within the perfusion profile.
3) Noradrenaline dose-time interaction.
In order to clarify and quantify the effects of 
perfusion with increasing noradrenaline concentrations, a 
oneway analysis of variance followed, where appropriate, by 
Duncan’s multiple range test (alpha = 0.05) was carried out 
using mean secretion rates calculated for the total perfusion 
period and also for individual secretion phases (as 
previously defined). A comparison of warm versus cold data 
at each noradrenaline dose was made using repeated measures 
two way analysis of variance of secretion profiles followed, 
where appropriate, by oneway analysis of variance of mean 
secretion rates calculated for the total perfusion period and 
also for individual secretion phases.
6.3 Results
6.3*1 Warm Acclimated Animals
The mean body weight of the warm acclimated animals 
used in the noradrenaline dose response studies was 317.5 + 
8.3g with no significant differences between rat groups. 
Mean BAT and dry pancreatic weights were 128.0 +8.2 mg and 
92.6 + 4.8 mg respectively, again no significant differences 
between rat groups was observed apart from a significantly 
greater BAT weight of the rat group used for perfusion with 
100 ng/100 mis noradrenaline (p<0.05).
p<
DOSE EFFECT 0.0400
TIME EFFECT 0.0001
DOSE/TIME INTERACTION 0.0001
Table 6.1 - Repeated measures two way analysis of
variance showing the effects of noradrenaline-dose, time, 
and dose-time interaction on the glucagon secretion 
profile in the warm acclimated animal.
Mean glucagon secretion profiles for each 
noradrenaline dose are presented in Appendix 1(A.5 - A.8) and 
in graphically Figure 6.1 (All values are expressed as the
mean + S.E.M.).
Repeated measures two-way analysis of variance 
indicates a significant effect of noradrenaline dose, 
perfusion time and dose-time interaction as indicated in 
Table 6.1.
Oneway analysis of mean secretion rates, followed by 
Duncan’s Multiple Range Test, is summarised in Table 6.1 and 
in Figure 6.2. The mean glucagon secretion rate over the 
total 25 minute perfusion period increased with increased 
noradrenaline dose, but significance was only achieved when 
perfusing with a dose of 100 ng/100 mis Noradrenaline,
reaching a value of 208% of control.
Of the secretion phases analysed only mean phase 1 
values were affected by perfusion with noradrenaline and 
showed a significantly greater mean secretion rate at a 
minimum noradrenaline concentration of 40 ng/100mls of 
perfusate. Maximum noradrenaline stimulation caused a rise 
in mean phase 1 secretion rate to 428% of control.
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6.3.2 Cold Acclimated Animals
The mean body weight of the cold acclimated animals 
used in the noradrenaline dose response studies was 336.4 +
7.3 mg with no significant differences between groups. Mean 
BAT and dry pancreatic weights were 182.5 + 11.8 mg and 90.1 
+5.4 mg respectively with no significant differences 
observed between animal groups. Both the mean body weight 
and BAT weight of the cold acclimated animals used for the 
noradrenaline perfusion studies were significantly greater 
than the mean body and BAT weights of the equivalent warm 
acclimated animals used for noradrenaline perfusion studies 
(p<0.05), in keeping with the results in Chapter 5.
Mean glucagon secretion profiles for each 
noradrenaline dose are summarised in Appendix 1 (A.9 - A.12) 
and graphically in Figure 6.3. Repeated measures two-way 
analysis of variance indicates a signficant effect of 
noradrenaline dose, perfusion time and dose-time interaction 
as shown in Table 6.3. One way analysis of mean secretion 
rates, followed by Duncan’s multiple range Test, is 
summarised in Table 6.4 and Figure 6.4.
p<
DOSE EFFECT 0.0490
TIME EFFECT 0.0010
DOSE/TIME INTERACTION 0.0070
Table 6.3 - Repeated measures two way analysis of
variance showing the effects pf noradrenaline-dose, time 
and dose-time interaction on the glucagon secretion 
profile in the cold acclimated animal.
Mean glucagon secretion rates for the total 25 minute 
perfusion period increased with increased noradrenaline 
concentration, with a minimum dose of 40 ng/100 mis of
perfusate causing significant rise above control values. 
Maximum noradrenaline stimulation caused a rise in mean total 
secretion to 274% of control values.
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Both phase 1 and phase 2 mean secretion rates showed 
effects of increased noradrenaline dose with a minimum dose 
of 40 ng/100 mis required to cause a significant rise above 
control values. Maximum noradrenaline stimulation caused a 
significant rise in phase 1 and phase 2 mean secretion rates 
to 203% and 306% of control values respectively.
6.3.3 Noradrenaline Effects Warm Versus Cold
Analysis of variance of warm versus cold groups for 
each individual noradrenaline dose and for all noradrenaline 
doses showed no significant effects of cold acclimation on 
the modulation by noradrenaline of basal or
arginine-stimulated glucagon secretion.
6.4 Discussion
6.4.1 Noradrenaline Dose-Response Effects in the Warm 
Acclimated Animal
The data indicates no effect of exogenous 
noradrenaline on basal glucagon secretion. This is in accord 
with Pipeleers et al (1985b) who suggested that stimulation 
of the A cell could not occur in the absence of an amino acid 
stimulus. The stimulatory effect of exogenous noradrenaline
on arginine stimulated glucagon secretion from the isolated 
perfused pancreas is in agreement with other studies which 
have demonstrated a stimulatory effect of noradrenaline on 
plasma glucagon concentrations in vivo in the dog (Raum et al 
1984; Ribes et al 1984) and on arginine stimulated glucagon 
release in vitro in the rat (Weir et al 1974) and dog 
(Iversen 1973a). There is much evidence to suggest that this 
stimulatory effect is via beta adrenoceptor stimulation as 
indicated by studies on the effects of isoproterenol in the 
dog (Iversen et al 1973; Kaneto et al 1975) and rat (Gerich 
et al 1974) and by the use of alpha and beta antagonists 
administered concomittantly with noradrenaline (Iversen 
1973a). It is of interest to note that only Phase 1 of 
glucagon release was stimulated by noradrenaline in this 
study.
6.4.2 Noradrenaline Dose-Response Effects in the Cold
Acclimated Animal
The glucagon responses to noradrenaline in the cold 
acclimated group differ from the warm control group in that, 
in the former, when a stimulatory effect of noradrenaline was 
seen, both phase 1 and phase 2 secretion rates were
significantly raised with respect to the zero dose, whereas
in the warm group when noradrenaline stimulation was 
recorded, only Phase 1 was involved. As a result the minimum 
effective dose resulting in an enhanced arginine-stimulated 
glucagon release over the total perfusion period is lower in 
the cold-acclimated animal thereby, implying an enhanced
sensitivity to noradrenaline in the cold acclimated group. 
However it must be noted that no significant differences in 
glucagon output between warm and cold groups at any 
noradrenaline dose were observed.
Thus there appears to be an enhanced glucagon release 
in response to exogenous noradrenaline in the isolated 
perfused pancreas of the cold acclimated group as indicated 
by an enhanced responsiveness of basal and phase 2 secretion 
which is in turn reflected by an enhanced overall response to 
noradrenaline. This is in agreement with Kuroshima, Habara 
and Ohno (1983) who also showed an enhanced glucagon response 
to exogenous noradrenaline infusion in vivo.
7 ADRENERGIC BLOCKADE IN THE WARM AND THE COLD
7.1 Introduction
It has already been indicated that there is 
controversy over the adrenergic regulation of glucagon 
release, with much conflicting evidence as to the role of 
alpha and beta adrenergic mechanisms. A stimulatory role for 
the beta adrenoceptor has been demonstrated during electrical 
stimulation of the splanchnic nerve of the dog (Kaneto et al 
1975b), hypoglycemia stimulated glucagon secretion in the 
baboon (Asplin et al 1985), exercise-induced glucagon release 
in the rat (Luyckx and Lefebvre 1974) and by the stimulation 
of glucagon release with the beta agonist isoproterenol in 
both the dog (Kaneto et al 1975a; Iversen 1973a) and the rat 
(Gerich et al 1974b). However an inhibitory influence of 
isoproterenol has been demonstrated in the duck (Tyler et al 
1972) and in the rat (Toyota et al 1975).
Similarly, a stimulatory role for the alpha 
adrenoceptor has been demonstrated during
hypoglycemia-induced glucagon release in the baboon (Asplin 
1985), stress-induced glucagon secretion in the rat (Nakhooda 
et al 1981), exercise-induced glucagon secretion in the rat 
(Harvey et al 1974) and by methoxamine (alpha agonist) 
stimulation of glucagon secretion in the rabbit (Knudtzon 
1984). Conversely studies have also shown an inhibitory role 
of the alpha adrenoceptor in the rat during exercise-induced
glucagon secretion (Luyckx and Lefebvre 1974), with the use 
of alpha agonist phenylephrine (Narimiya et al 1981), and 
with the combined use of the alpha agonist methoxamine and 
antagonist phentolamine (Gerich et al 1974). Thus the 
possible adrenergic mechanisms of any cold induced changes in 
glucagon secretion via increased sympathetic activity are far 
from clear, although studies by both Helman et al (1984) and 
Sasaki et al (1982), in the rat and the sheep, have shown a 
stimulatory role for the alpha adrenoceptor in cold-induced 
increases in glucagon.
The purpose of this third set of experiments was; 1) 
to investigate adrenergic regulation of glucagon secretion in 
the warm acclimated animal and 2) to evaluate any changes in 
these regulatory mechanisms when an animal is subjected to 
prolonged cold exposure, in order to elucidate further the 
role of adrenergic regulation in the cold acclimated animal. 
Thus an assessment was made of changes in basal and arginine 
stimulated glucagon release from the isolated perfused 
pancreas of both warm and cold acclimated animals treated 
chronically for 1 week with either phentolamine (alpha 
blocker) or propranolol (beta blocker). Phentolamine and 
propranolol were chosen because they were not specific to 
adrenoceptor subtype.
7.2 Methods
A group of warm acclimated animals and a group of cold 
acclimated animals were dosed chronically for one week prior 
to perfusion experiments with either phentolamine (0.125 
mg/kg s.c. 2 x daily for 7 days) or with propranolol (0.7 
mg/kg s.c. 2 x daily for 7 days), as described in chapter 2. 
Pancreata were perfused and the outputs assayed for glucagon 
using the methods described in Chapters 2 and 3.
For both warm and cold sets of data repeated measures 
two way analysis of variance of glucagon secretion rates 
using all three experimental groups (untreated, 
phentolamine-treated and propranolol-treated) was carried out 
as previously described, using all 25 time points of the 
secretion profile to indicate the significant effects of;
1) Drug treatment.
2) Time effects within the perfusion profile.
3) Drug-time interaction.
In order to clarify the effects of drug treatment, 
where significant effects were established a oneway analysis 
of variance followed, where appropriate, by Duncan’s multiple 
range test (alpha = 0.05) was carried out using mean
secretion rates calculated for the total perfusion period and 
for individual secretion phases.
7.3 Results
7.3.1 Warm Acclimated Animals
Mean body weights, BAT weights and dry pancreatic 
weights (mg/100g body weight) for each group are given in 
Table 7.1. No significant difference in body or BAT weights 
were found, although the mean pancreatic weight of the 
phentolamine treated group was less than that of the warm 
acclimated control group (P<0.05).
DRUG
TREATMENT
RAT
WEIGHT
(g)
PANCREATIC DRY 
WEIGHT 
(mg/100g)
BROWN FAT 
WEIGHT 
(mg/100g)
MEAN SEM MEAN SEM MEAN SEM
Untreated 308.5 + 6.8 96.9 + 9.2 144.1 + 16.3
Phentol 305.7 + 6.8 68.6 + 4.5 128.6 + 19.0
Propran 318.6 + 7.4 82.6 + 5.7 111.7 + 16.6
Table 7.1 - Body and tissue weights of warm acclimated
animal groups treated with phentolamine or propranolol.
Mean glucagon secretion profiles for each group are 
presented in Appendix 1 (A.13 and A.14) and graphically in 
Figure 7.1. Repeated measures two-way analysis of variance 
indicates a significant effect of treatment, perfusion time 
and treatment-time interaction as indicated in Table 7.2.
p<
DOSE EFFECT 
TIME EFFECT 
DOSE/TIME INTERACTION
Table 7.2 - Repeated measures two way analysis of
variance showing the effects of drug treatment 
(adrenergic blockade), time and drug-time interaction on 
the glucagon secretion profile in the warm acclimated 
animal.
Oneway analysis of mean secretion rates, followed by 
Duncan’s Multiple Range Test, are summarised in Table 7.3 and 
Figure 7.2.
The mean glucagon secretion rate for the total 25 
minute perfusion period was significantly elevated in the 
phentolamine-treated group to 197% of warm control values. 
Of mean basal secretion rates only the propranolol-treated 
group showed an effect, with a significant reduction to 28% 
of values for the group treated with phentolamine. Mean 
phase 1 secretion was significantly elevated in the 
phentolamine group to 434% of warm control values. No 
effects of propranolol treatment were observed in phase 1 
secretion rates. Analysis of mean phase 2 secretion showed a 
significant effect of both drug treatments, with phentolamine 
causing a rise in secretion rates to 169% of warm control 
whilst proranolol caused a significant reduction to 40% of 
warm control values.
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7.3.2 Cold Acclimated Animals
Mean body weights, BAT weights and dry pancreatic 
weights (g/100g body weight) for each group are given in 
Table 7.4. No significant differences were observed in body 
weights, BAT weights or dry pancreatic weights. All cold 
acclimated animal groups treated with phentolamine or 
propranolol had significantly greater body weights and BAT 
weights than the warm acclimated animal groups treated with 
phentolamine or propranolol (P<0.05).
DRUG RAT DRY PANCREATIC BROWN FAT
TREATMENT WEIGHT WEIGHT WEIGHT
(g) (mg/100g) (mg/100g)
MEAN SEM MEAN SEM MEAN SEM
Untreated 348.3 + 8.6 102.3 + 6.2 200.1 + 22.8
Phentol 341.8 + 9.6 95.0 + 4.7 163.9 + 10.9
Propran 336.8 + 8.2 102.9 + 2.6 182.6 + 8.3
Table 7.4 - Body and tissue weights of cold acclimated
animal groups treated with phentolamine or propranolol.
p<
DRUG EFFECT 0.0630
TIME EFFECT 0.0001
DRUG/TIME INTERACTION 0.0001
Table 7.5 - Repeated measures two way analysis of 
variance showing the effects of drug treatment
(adrenergic blockade), time and drug-time interaction on 
the glucagon secretion profile in the cold acclimated 
animal.
Mean glucagon secretion profiles for each group are 
presented in Appendix 1 (A.15 and A.16) and graphically in 
Figure 7.3. Repeated measures two-way analysis of variance 
showed no significant effect of treatment although 
significant effects of perfusion time and treatment-time 
interaction were observed as indicated in Table 7.5. Oneway 
analysis of mean secretion rates followed, where appropriate, 
by Duncan’s Multiple Range Test, are summarised in Table 7.6 
and Figure 7.4.
No effect of drug treatment, in the cold, was observed 
on total mean secretion rates. Of the time phases analysed 
only phase 1 secretion rates showed a significant effect of 
treatment with phentolamine causing a reduction in mean phase 
1 secretion rates to 30% of cold control values. No effect 
of propranolol treatment was observed on glucagon secretion 
rates.
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7,3.3 Adrenergic Blockade Warm versus Cold
Phentolamine Treated Groups - Repeated measures 
two-way analysis of variance showed significant effects of 
cold environment, perfusion time and cold-time interaction as 
indicated in Table 7.7. Oneway analysis of variance of mean 
secretion rates is presented in Table 7.8.
The mean secretion rate for the total perfusion period 
was significantly reduced in the cold acclimated 
phentolamine-treated group to a value 31.9% of the warm 
acclimated phentolamine-treated group. Similarly basal, 
phase 1 and phase 2 secretion rates were reduced in the cold 
acclimated phentolamine-treated groups to 12.7%* 12.8% and
40% of the warm acclimated phentolamine-treated group 
respectively.
p<
COLD EFFECT 0.0001
TIME EFFECT 0.0001
COLD/TIME INTERACTION 0.0001
Table 7.7 - Repeated measures two way analysis of
variance showing the effects of cold exposure, time and 
cold-time interaction on the glucagon secretion profile 
in the phentolamine-treated animal.
SECRETION
PHASE
GROUP GLUCAGON OUTPUT 
ng/min/g pane 
MEAN SEM
DF Fs P<
TOTAL WA 10.489 + 1.344 1,13 34.332 0.0001
CA 2.226 + 0.456
BASAL WA 2.279 + 0.589 1,13 11.343 0.0056
CA 0.291 + 0.037
PHASE 1 WA 34.459 + 4.910 1,13 35.009 0.0001
CA 4.435 + 1.277
PHASE 2 WA 10.417 + 1.292 1,13 32.150 0.0010
CA 2.527 + 0.515
Table 7.8 - Oneway analysis of variance of mean glucagon secretion
rates from the IPP of phentolamine-treated animals using warm 
acclimated (WA) and cold acclimated CA) animal groups (Total 
secretion 1-25 min, Basal secretion 1-5 min, Phase 1 secretion 6-7 
min, Phase 2 secretion 9-25 min).
Propranolol Treated Groups - Repeated measures two-way 
analysis of variance showed no significant effect of cold 
environment, although significant effects of perfusion time 
and cold-time interaction were observed, as indicated in 
Table 7.9. Oneway analysis of variance of mean secretion 
rates is presented in Table 7.10. No significant differences 
were seen between mean secretion rates over the total 
perfusion period, although phase 1 secretion in the cold 
acclimated phentolamine-treated groups were significantly 
higher, with values 217% of the warm acclimated 
propranolol-treated groups.
p<
COLD EFFECT 0.0900
TIME EFFECT 0.0001
COLD/TIME INTERACTION 0.0001
Table 7.9 - Repeated measures two way analysis of
variance showing the effects of cold exposure, time and 
cold-time interaction on the glucagon secretion profile 
in the propopranol-treated animal.
SECRETION
PHASE
GROUP GLUCAGON OUTPUT 
ng/min/g pane 
MEAN SEM DF F P<
TOTAL WA 2.275 + 0.258 13 3.412 0.0895
CA 3.582 +. 0.658
BASAL WA 0.648 + 0.132 13 2.404 0.1470
CA 0.419 + 0.064
PHASE 1 WA 4.454 + 0.741 13 5.560 0.0362
CA 9.667 + 2.002
PHASE 2 WA 2.503 + 0.299 13 2.251 0.1593
CA 3.830 + 0.832
Table 7.10 - Oneway analysis of mean glucagon secretion rates from the
IPP of propranolol-treated animals using warm acclimated (WA) and cold 
acclimated (CA) animal groups (Total secretion 1-25 min, Basal secretion 
1-5 min, Phase 1 secretion 6-7 min, Phase 2 secretion 9-25 min).
7.4 Discussion
7.4.1 Adrenergic Blockade in the Warm Acclimated Animal
The role of the sympathetic nervous system in 
elevating plasma glucagon concentrations in response to 
various stressful stimuli is well established (Harvey et al 
1974; Nakhooda et al 1981; Bloom 1973; Helman et al 1984).
However the role of the sympathetic nervous system in 
controlling glucagon release in the unstressed animal is 
unclear. Use of alpha and beta antagonists both in vivo and 
in vitro has provided conflicting results. Infusions of 
phentolamine in man (Gerich et al 1974; Chap, Ischida, Chou, 
Michael, Hartley, Entman and Field 1986) produced an increase 
in plasma glucagon, as did intraperitoneal injections in the 
rat (Luyckx and Lefebvre 1974), whilst Sasaki et al (1982) 
showed an inhibitory effect of phentolamine infusion on 
glucagon secretion in the sheep. In vitro studies have been 
unable to show any effect of perfusion with phentolamine on 
glucagon secretion in the dog (Iversen et al l973a) or in the 
rat (Nariiniya et al 1981). The aforementioned in vivo and in 
vitro studies showed no effect of propranolol on basal 
glucagon secretion.
However, studies by Undenfriend et al (1968) have 
indicated that alpha blockade causes hypotensive pressor 
effects which cause appropriate baroreceptors to stimulate a
compensatory increase in sympathetic activity. It is 
possible that such an increase in sympathetic activity during 
the 1 week prior to perfusion in the warm acclimated animal 
would be similar to acute cold exposure in its effects on the 
sympathetic nervous system, and thus enhance
arginine-stimulated glucagon secretion by the isolated 
perfused pancreas. This might explain the secretory response 
to arginine in the isolated perfused pancreas after chronic 
treatment with phentolamine which appeared to be maximal, ie 
of the same magnitude as the response induced by the maximum 
noradrenaline dose and by 2 weeks cold exposure. The data 
therefore may not give reliable indications of the possible 
effects of alpha-blockade on glucagon secretion from the 
isolated perfused pancreas in the warm acclimated animal.
Chronic treatment with propranolol for one week prior 
to perfusion showed a significant reduction in second phase 
secretion of arginine-stimulated glucagon release from the 
isolated perfused pancreas. This suggests a basal tonic 
stimulatory role of beta adrenergic agonism in the control of 
glucagon secretion in the warm acclimated rat. This is in 
agreement with Lawrence, Ajlouni and Hagen (1984) who were 
able to show a reduction in both basal and 
hypoglycemia-stimulated glucagon release after chronic 
treatment with propranolol. Other workers, however, were 
unable to show an effect on propranolol on glucagon release 
in the absence of increased sympathetic activity either in 
vivo (Gerich et al 1974b; Chap et al 1986; Luyckx and 
Lefebvre 1974; Sasaki et al 1982) or in vitro (Iversen 1973; 
Nariiniya et al 1981). Studies of chronic propranolol 
treatment in the rabbit (Raine and Chubb 1977) have indicated
a reduced sympathetic activity as reflected by reduced 
tyrosine hydroxylase and dopamine beta hydroxylase, although 
similar studies in man measuring basal plasma noradrenaline 
levels were unable to show an effect of chronic treatment 
with propranolol (Benedict, Pickering and Raine 1977). Thus 
it is possible that a reduction in sympathetic acivity as a 
result of chronic propranolol treatment might contribute to 
the reduction in glucagon secretion observed in the warm 
acclimated propranolol-treated animal.
7.4.2 Adrenergic Blockade in the Cold Acclimated Animal
The effect of alpha blockade in the cold acclimated 
group is markedly different from that in the warm acclimated 
group of rats. The disappearance of the stimulatory effect 
of chronic phentolamine treatment (postulated to be the
result of a compensatory increase in sympathetic activity) on 
glucagon secretion, demonstrates clearly that after six weeks 
exposure to cold, increased sympathetic stimulation does not 
result in an increased glucagon secretion. The replacement 
of this response by an inhibition of glucagon secretion
suggests that despite a postulated unresponsiveness to
sympathetic stimulation (in vivo), the A cell is still under 
a degree of adrenergic control with an implied stimulatory
action for the alpha adrenoceptor. Whilst no other studies 
have investigated the adrenergic mechanisms that might be 
involved in such changes in A cell sensitivity during cold
acclimation, studies investigating adrenergic control of 
acute cold-induced increases in glucagon secretion have found 
a similar inhibition of glucagon release during alpha 
blockade. Thus Sasaki et al (1982) found, in the sheep, 
suppression of the cold-induced enhanced arginine-stimulated 
glucagon after infusion with phentolamine. Similarly Helman 
et al (1984) showed that hypothermia-induced increases in 
basal glucagon in the rat were reduced during an infusion of 
phentolamine, although the enhanced glucagon response to 
arginine was unaffected. It is also possible that a reduced 
inhibitory effect of noradrenaline on the B cell might also 
contribute to the suppression of glucagon secretion after 
alpha blockade in the cold acclimated animal. Certainly 
Baroody (1979) demonstrated that an identical chronic 
treatment with phentolamine (0.125 mg/kg s.c. 2 x daily for 
7 days) served to partially remove the inhibitory influence 
of chronic cold exposure on insulin secretion, although it is 
unlikely that this is a major contributory factor, as 
evidenced in this study by unaltered glucagon secretion from 
the isolated perfused pancreas of the cold acclimated animal 
despite chronically suppressed insulin secretion.
The disappearance of the inhibitory effect of 
propranalol seen in the warm acclimated group after 6 weeks 
cold exposure, similarly supports the idea of a reduced A 
cell responsiveness to sympathetic modulation in vivo in the 
cold acclimated animal.
8 GENERAL DISCUSSION
8.1 The Physiological Significance of Changes in Glucagon 
Secretion from the Isolated Perfused Pancreas of the Cold 
Acclimated Rat
There is substantial evidence within this study to 
indicate a significant effect of varied cold exposure on 
glucagon secretion from the isolated perfused pancreas. 
However in assessing the significance of these in vitro data 
it is important to consider the numerous physiological 
factors involved in control of glucagon secretion, absent 
from the isolated perfused pancreas but present in vivo, and 
to what extent these could modify the A cell response to cold 
exposure as reflected by the isolated perfused pancreas.
Substrate Mix - In vivo the pancreas receives a 
constantly fluctuating substrate mix containing a combination 
of numerous amino acids (3-5 mM) (Pagliara et al 1974, 
Milakofsky, Hare, Miller and Vogel 1984), free fatty acids 
(324 mM Kuroshima et al 1978), and glucose (4-6 mM Kuroshima 
et al 1978). This is in contrast to the isolated perfused 
pancreas preparation which is perfused with a high (10 mM) 
arginine concentration during stimulation, and a glucose 
concentration (4 mM) which is at the threshold for insulin 
secretion (Ashcroft, Bunce, Bassett and Randle 1972). 
Although an amino acid mix is a more potent stimulus of 
glucagon secretion than an equimolar concentration of any one
amino acid (Assan et al 1977), it has been indicated that a 
10 mM arginine concentration as used here would be of greater 
potency than any in vivo amino acid mix (Gerich et al 1974a). 
The presence of a constant low glucose concentration would 
similarly minimise the inhibitory glycemic influence on 
glucagon release, whilst maintaining B-cell responsiveness 
(Gerich et al 1974a). The absence of free fatty acids might 
also serve to enhance the observed glucagon release from the
isolated perfused pancreas compared to the in vivo state.
(Luyckx and Lefebvre 1970).
Thus within the isolated perfused pancreas the 
glucagon response to perfusion with the stimulatory medium 
would reflect a (near) maximal nutrient-stimulated release. 
Considerable attenuation of this response might be expected 
to occur in vivo. During cold exposure, an increased 
turnover of free fatty acids and glucose is observed (Portet
et al 1974; Depocas 1959; 1962), although absolute plasma
levels of substrate remain unaltered. Therefore substrate 
modulation, in vivo, of the maximum secretory potential as 
reflected by the isolated perfused pancreas would probably be 
similar in both warm and cold acclimated animals.
Neural influences - During isolation of the pancreas 
both vagal and splanchnic nerves providing autonomic 
innervation to the pancreas are severed. However, there is 
evidence to suggest that intrinsic pancreatic neural 
mechanisms remain intact and functional (Hisatomi et al 
1985). Thus it is not likely that all neural influences 
within the pancreas are removed. However central nervous 
control of pancreatic secretion is lost and therefore
cold-induced increases in sympathetic tone to the pancreas 
and the resultant stimulation of glucagon secretion may be 
attenuated in the isolated perfused pancreas.
Hepatic clearance - There is evidence indicating that 
in the rat, as in other animals, peripheral levels of both 
insulin and glucagon are modified within the liver by hepatic 
clearance (Balks and Jungermann 1984). These same studies 
also show that these clearances can be modified by 
nutritional status. Thus after a meal there is a greater 
clearance of glucagon resulting in increased insulin:glucagon 
ratios, whilst during starvation increased hepatic clearance 
of insulin occurs, with a reduction in glucagon clearance 
thereby reducing the insulin:glucagon ratio and allowing 
mobilisation of energy substrates. It is therefore possible 
that cold exposure with the associated increase in energy 
requirements might also modify hepatic clearance to produce 
similary reduced insulinrglucagon ratios, so enhancing the 
adaptive changes in pancreatic hormone secretion described 
here.
Estimates of glucagon secretion from the isolated 
perfused pancreas in the absence of both the attenuating 
influence of an in vivo substrate mix and the modulating 
effects of neural and hormonal components cannot be said to 
reflect accurately pancreatic secretion in vivo, still less 
normal circulating hormone concentrations in the absence of 
hepatic degradation. Similarly it is possible that cold 
induced modulation of A cell secretion via neural and 
hormonal components that are absent in vitro might serve to 
modulate the response to cold exposure as reflected by the
isolated perfused pancreas. However, it is suggested that 
data from the isolated perfused pancreas does reflect the 
maximum secretory potential of the A cell and reflects in 
vivo changes in A cell sensitivity to specific stimuli, as 
the result of cold exposure.
8.2 Implications for the Role of Glucagon in the Cold Exposed 
Animal
A significantly enhanced arginine-stimulated glucagon 
secretion is seen in the isolated perfused pancreas after two 
and four weeks of exposure to cold, with a return to control 
values after six weeks, associated with a progressive 
decrease in insulin secretion. The proposal that these 
changes in pancreatic hormone secretion are related to the 
process of cold acclimation is supported by the concurrent 
effect of low environmental temperature on BAT mass. The 
data from this study indicates that after four and six weeks 
of cold a significant increase of 124% and 138% respectively 
over warm control values is observerd. This is in agreement 
with other workers who have found similar increases after 
cold exposure for a period of 3-4 weeks (Senault et al 1981; 
Desautels et al 1978; Thompson et al 1969 and Bukowiecki _et 
al 1982). Studies of the trophic response of BAT have 
indicated that related to the increase in BAT mass there are 
specific increases in BAT mitochondriogenesis, GDP-binding 
and the specific 32K mitochondrial protein (Trayhurn et al 
1983). There is much evidence to suggest that this trophic 
BAT response is associated with the development of an
enhanced thermogenic response to noradrenaline (Bukowiecki et_ 
al 1982) which is believed to reflect the transition fron 
shivering to nonshivering thermogenesis, at which point the 
animal can be said to be cold acclimated (Jansky 1973).
In the light of indications from this study of changes 
in pancreatic hormone secretion in response to chronic cold 
exposure, it is necessary to consider the possible role of 
glucagon in the physiological response to cold.
It is established that glucagon is a hormone of energy 
supply (Cryer 1984; Unger et al 1980), functioning in 
situations of energy need to supply substrate, as in the case 
of exercise (Wasserman, Lickley and Vranic 1984) and fasting 
(Unger and Orci 1981) through its stimulatory action on 
hepatic glycolysis and gluconeogenesis (Park and Exton 1972). 
That an increased mobilisation and utilisation of glucose 
occurs in response to acute and chronic cold exposure is well 
documented (Depocas 1959; 1960; Minaire et al 1973;
Cunningham 1985). Therefore it is possible that the enhanced 
glucagon response seen within the first four weeks of cold 
exposure contributes to the mobilisation of carbohydrate in 
response to the increased energy demands of cold induced 
thermogenic processes.
Similarly, the lipolytic action of glucagon under 
certain physiological conditions, particularly in conditions 
of reduced insulin secretion as demonstrated during cold 
exposure during this study, is well established (Liljenquist 
et al 1974; Schade et al 1979). The main energy substrate 
utilised during cold-stimulated thermogenic processes is free
fatty acids (approximately 75%) as demonstrated by Minaire jet 
al (1973). Thus the action of glucagon to mobilise free 
fatty acids could also be of importance in the provision of 
energy substrates during cold exposure.
Although evidence suggests that the major function of 
glucagon in cold exposure is to mobilise systemic energy 
substrates to fuel the increased thermogenic response, there 
is some evidence implicating glucagon in other aspects of the 
physiological response to cold acclimation.
In view of the reported calorigenic action of glucagon 
(Doi and Kuroshima 1982), it is tempting to speculate that 
glucagon, through its lipolytic action, might be involved in 
the stimulation of non-shivering thermogenesis within BAT of 
cold acclimated animals. Certainly there is much evidence of 
an enhanced sensitivity to uncoupling concentrations of free 
fatty acids within BAT mitochondria, conferred by the 
presence of the 32K mitochondrial protein in the cold 
acclimated animal (Locke et al 1982a). Evidence of an 
enhanced thermogenic response in the cold acclimated animal 
to glucagon both in vivo (Doi et al 1981, 1982; Barre and
Rouanet 1983) and in vitro (Kuroshima and Yahata 1979) 
supports the possibility of such a role, although it must be 
noted that supraphysiological doses were required to elicit 
such responses. Studies indicating an enhanced 
cardiovascular response to glucagon in the cold acclimated 
animal resulting in an increased blood flow to BAT (Yahata _et 
al 1983), might also suggest a possible involvement in the 
increase in blood flow to BAT in the cold acclimated animal. 
There are also studies indicating that chronic treatment with
glucagon can elicit the same developmental changes in BAT 
seen in response to chronic cold exposure, (Yahata et al 
1981). Thus the possibility of an involvement of the 
enhanced glucagon release observed during these studies, in 
the development of the cold acclimated state cannot be 
excluded. Although again, it must be stressed that no such 
effects have been demonstrated with physiological 
concentrations of glucagon, therefore the physiological 
significance of this data must be questioned.
Kuroshima et al (1978) has suggested that a return of 
plasma glucagon levels to control values after four weeks 
cold exposure is associated with the development of an 
enhanced BAT sensitivity to glucagon. However in this study 
a decline in enhanced glucagon secretion does not occur until 
after six weeks of cold exposure. Whether this difference 
reflects the existence of other modulating mechanisms in vivo 
which are not apparent in the isolated perfused pancreas 
(such as hepatic clearance) remains unanswered. However the 
continued, progressive reduction in insulin secretion, with 
the associated loss of its antilipolytic influences on the 
lipolytic action of glucagon (Schade et al 1979) might well 
result in an enhanced sensitivity to the lipolytic effects of 
glucagon. In view of this modulating influence of insulin on 
glucagon action it is perhaps of more physiological 
significance to consider changes in insulin:glucagon molar 
ratios.
This study demonstrates a marked reduction in 
insulin:glucagon molar ratios after 2 weeks cold exposure, 
which is maintained for the duration of the cold acclimatory
period under investigation. There is evidence to suggest 
(Unger 1971) that this reduction in insulin:glucagon molar 
ratio is indicative of a predominantly catabolic state, thus 
the effects of such a reduced insulin:glucagon molar ratio 
may well contribute to the cold-induced catabolic state in 
which there is an increased substrate mobilisation and 
utiltisation related to the increased thermogenic activity 
within the cold acclimated animal.
8.3 Glucagon Secretion and its Adrenergic Regulation in the 
Cold
It is postulated that the enhanced arginine-stimulated 
glucagon secretion observed after 2 and 4 weeks cold exposure 
is the result of an increase in sympathetic activity, which 
also results in a progressive decrease in insulin secretion. 
At 6 weeks however the enhanced glucagon release disappears, 
whilst insulin secretion levels remain low. It is suggested 
that the chronic adrenergic stimulation of the pancreas 
results in a desensitisation of the pancreatic A cell to the 
stimulatory effect of increased sympathetic activation. 
Further evidence of this has been obtained using alpha and 
beta antagonists, suggesting a basal stimulatory tone for for 
beta adrenoceptor stimulation of the A cell in warm 
acclimated rats which is abolished after six weeks cold 
exposure. A marked increase in glucagon secretion after 
phentolamine treatment in the warm acclimated animals is 
considered to be an experimental artifact resulting from the 
hypotensive effects of alpha blockade and causing a
baroreceptor stimulated increase in sympathetic activity „ 
This response was similarly abolished in the cold acclimated 
rat, with evidence of alpha adrenergic stimulatory control of 
A cell secretion during cold acclimation.
Chronic catecholamine stimulation has been shown to 
result in the desensitisation of the beta adrenergic 
receptor/adenylate cyclase system in numerous organs and 
tissues (Kebabian, Zatz, Romero and Axelrod 1975; Mukherjee, 
Caron and Lefkowitz 1975; Johnson, Wolfe., Harden, Molinoff 
and Perkins 1978). Changes in adrenergic sensitivity in 
response to cold exposure have been investigated primarily in 
BAT. Evidence suggests that despite an enhanced thermogenic 
response to beta adrenoceptor stimulation there is a down 
regulation of beta adrenoceptor numbers due to chronic 
stimulation with noradrenaline (Bukowiecki et al 1978; 
Nedergaard 1982), and that these receptors also appear to 
become uncoupled from the adenylate cyclase complex 
(Svartengren et al 1982). Conversely there is an apparent 
upregulation of alpha adrenoceptors which, it has been 
postulated, might potentiate beta receptor activity (Mohell, 
Nedergaard and Cannon 1983).
The effects of cold exposure on pancreatic adrenergic 
regulatory mechanisms are unclear. There is certainly 
evidence of an increased pancreatic noradrenaline turnover 
during acute cold exposure (Young and Landsberg 1979) and 
evidence of a generally enhanced sympathetic activation after 
chronic cold exposure as indicated by elevated urinary levels 
(LeBlanc and Nadeau 1961; Leduc 1961). Thus the apparent 
unresponsiveness of the A cell after 6 weeks cold exposure
might be due to a similar down regulation of beta receptors 
as a result of chronic sympathetic stimulation. A reduced 
pancreatic beta adrenergic sensitivity is not incompatible 
with the progressive reduction in insulin secretion observed 
during cold acclimation. Indeed studies by Baroody (1979), 
using cold acclimated phentolamine treated rats demonstrated 
an insulin secretion rate which, while greater than that seen 
in untreated cold acclimated animals, was significantly less 
than that in warm controls despite concomittant alpha 
blockade, and cold-induced enhanced beta adrenergic 
stimulation which might be viewed as evidence in support of 
such receptor changes. Studies by Rousseau-Migneron, Nadeau 
and Tancrede (1980) have also indicated a reduced insulin 
response to isoproterenol in vivo after chronic treatment (4 
weeks) with isoproterenol, although such chronic beta 
adrenergic stimulation had no effect on glucagon 
responsiveness.
The possibility of alpha adrenergic receptor 
upregulation is pure conjecture, but such an event could 
explain the continued progressive reduction in insulin 
secretion. It is also possible that this accounts for the 
significant inhibitory effect of alpha blockade upon glucagon 
secretion in the cold acclimated rat, whilst the inhibitory 
effect of propranolol seen in the warm control is abolished. 
However the existence of such receptor changes are, of 
course, entirely conjectural.
Similarly the possibility of dopaminergic and other 
peptidergic influences in the regulation of glucagon 
secretion in the cold acclimated animal cannot be discounted.
Certainly Helman et al (1984) were able to to show an 
inhibitory effect of haloperidol (a dopaminergic antagonist) 
on cold-induced increases in glucagon secretion. Other 
studies have also demonstrated stimulatory effects of 
dopamine although using pharmacological doses (LeBlanc, 
Lachelin, Abu-Fadil and Yen 1977), whilst Conell, Beastall, 
Davies and Buchanan (1986) were unable to show an effect upon 
glucagon secretion using physiological concentrations of 
dopamine.
However, the data presented for the noradrenaline
perfusion experiments in the warm and the cold appear to
conflict with the hypothesis of a reduced sensitivity to 
sympathetic stimulation in the cold acclimated rat, with a 
lower minimum dose of noradrenaline required to enhance 
arginine-stimulation of glucagon release in the cold 
acclimated rat than in the warm rat, implying an increased 
sensitivity of the cold acclimated rat to exogenous 
noradrenaline.
However comparison of the effects of chronic
sympathetic stimulation in vivo and perfusion with exogenous
noradrenaline in vitro on the A cell response to arginine 
stimulation in the isolated perfused pancreas must take into 
account the different routes of access of noradrenaline into 
the pancreas. In vivo noradrenaline is released from 
sympathetic nerve terminals adjacent to the islet cells, 
whilst when perfusing with noradrenaline, the catecholamine 
must enter the pancreas via the pancreatic vasculature. 
Foster et al (1980) showed a reduction in fractional 
distribution of cardiac output to the pancreas in response to
cold exposure or noradrenaline in the cold acclimated animal, 
but because of the overall increase in cardiac output in the 
cold acclimated animals the net effect was an increased flow 
rate to the pancreas in vivo. In the isolated perfused 
pancreas therefore, noradrenaline might be expected to cause 
a reduction in flow rate in the pancreas of the cold 
acclimated rat compared to that of the warm acclimated rat, a 
very different situation from that seen in vivo, where flow 
rate is increased. However the maintenance of constant flow 
rates by pressure adjustments should obviate any such 
vascular responses to noradrenaline, and flow rates for each 
group of perfusion experiments do not indicate any 
significant effect of noradrenaline. Also, volume 
adjustments have been made in an attempt to negate vascular 
changes and consequent dilution effects on glucagon outputs.
It is of interest to note that Kuroshima et al (1983) 
similarly found an increased glucagon response to 
noradrenaline infusion in the cold acclimated compared to the 
warm acclimated rat in vivo, whilst other work from the same 
laboratory (Kuroshima, Yahata and Habara 1984) showed a 
reduced glucagon response to acute cold exposure in the cold 
acclimated animal in vivo.
8.4 Suggestions For Further Work
In order to elucidate further the time course effects
of chronic cold exposure on glucagon secretion, it would be
useful to relate changes in glucagon secretion from the
isolated perfused pancreas to changes in both arterial plasma
glucagon concentrations and total pancreatic glucagon content 
throughout the 6 week cold acclimatory period studied. A 
similar assessment of plasma insulin concentrations and total 
pancreatic insulin content might also provide greater insight 
into the progressive changes taking place within the pancreas 
as the result of cold acclimation.
In an attempt to establish a causal role for 
pancreatic sympathetic activation in these hormonal 
responses, estimates of pancreatic noradrenaline turnover 
throughout the acclimation period might also prove useful. 
Similarly a more detailed examination of changes in 
pancreatic sensitivity to sympathetic stimulation, through 
the assessment of the dose-response effects within the 
isolated perfused pancreas of perfused noradrenaline on both 
insulin and glucagon secretion throughout the 6 week period 
might help to clarify progressive changes in pancreatic islet 
cell sensitivity during the process of acclimation.
In an attempt to elucidate adrenergic receptor 
mechanisms involved in the control of pancreatic secretion 
during cold acclimation (and the apparent changes in 
adrenergic sensitivity) it might prove useful to examine the 
effects, within the isolated perfused pancreas, of
concomittant perfusion with noradrenaline and phentolamine or 
propranolol and also the effects of selective alpha and beta 
agonists on both insulin and glucagon secretion.
Finally, in the light of other studies which have been 
able to mimic the effects of chronic cold exposure in terms 
of the BAT trophic response and the associated enhanced 
thermogenic response to noradrenaline, through the use of 
chronic administration of beta adrenergic agonists (Mory et 
al 1984; Leblanc et al 1972), it would be of great interest 
to see if such treatment could also reproduce the changes in 
glucagon secretion and adrenergic sensitivity demonstrated in 
this study.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/ml)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.36 + 0.08 0.164 + 0.061 0.872+ 0.302
2 1.35 + 0.07 0.211 + 0.076 1.030 + 0.342
3 1.36 + 0.07 0.169 + 0.053 0.872 + 0.255
4 1.54 + 0.16 0.212 + 0.066 1.293 + 0.444
5 1.47 + 0.14 0.400 + 0.241 1.919 + 0.837
6 1.13 + 0.11 2.322 + 1.037 10.539 + 5.087
7 1.21 + 0.05 1.176 + 0.282 5.321 + 1.091
8 1.23 + 0.03 1 .294 + 0.534 5.999 + 2.340
9 1.26 + 0.05 2.255 + 0.923 11.046 + 4.270
10 1.28 + 0.03 1 .932 + 0.643 9.498 + 2.716
11 1.29 + 0.03 1.319 + 0.558 6.298 + 2.440
12 1.31 + 0.04 1 .464 + 0.512 6.947 + 2.137
13 1.27 + 0.03 1.274 + 0.362 6.201 + 1.435
14 1.28 + 0.03 1.118 + 0.383 5.433 + 1.435
15 1.27 + 0.03 1.210 + 0.373 5.954 + 1.559
16 1.25 + 0.04 1.114 + 0.378 5.267 + 1.543
17 1.26 + 0.03 0.721 + 0.220 3.560 + 9.577
18 1.23 + 0.05 1.021 + 0.309 4.685 + 1.242
19 1.24 + 0.07 1.209 + 0.410 5.230 + 1.267
20 1.23 + 0.06 1.426 + 0.401 6.504 + 1.337
21 1.17 + 0.06 1.329 + 0.414 5.649 + 1.175
22 1.17 + 0.06 1.140 + 0.318 4.862 + 0.972
23 1.28 + 0.07 0.869 + 0.191 4.587 + 1.178
24 1.17 + 0.06 1.093 + 0.289 4.682 + 0.820
25 1.17 + 0.05 2.058 + 1.145 8.191 + 3.750
Table A.1 - glucagon secretion in the warm acclimated group.
All values are expressed as the mean + S.E.M, mean body
weight = 308.5 + 6.8 g n=8.
SAMPLE
TIME
(mins)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/ml)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.49 + 0.07 0.207 + 0.043 0.961 + 0.186
2 1.52 + 0.02 0.187 + 0.041 0.892 + 0.198
3 1.45 + 0.04 0.191 + 0.039 0.867 + 0.157
4 1.40 + 0.05 0.183 ■+ 0.035 0.818 + 0.144
5 1.46 + 0.01 0.174 + 0.036 0.787 + 0.154
6 1.36 + 0.08 11 .641 + 2.020 53.360 +11.963
7 1.48 + 0.03 5.307 + 2.559 24.882 + 9.216
8 1.44 + 0.03 1.616 + 0.370 7.914 + 1.476
9 1.47 + 0.01 1.943 + 0.281 9.690 + 1.581
10 1.45 + 0.04 2.280 + 0.356 10.956 + 1.708
11 1.43 + 0.04 2.516 + 0.516 11.891 + 2.274
12 1.50 + 0.02 1.922 + 0.362 9.542 + 1.873
13 1.42 + 0.03 1.885 + 0.376 9.095 + 1.763
14 1.38 + 0.04 1.827 + 0.337 8.410 + 1.496
15 1.48 + 0.02 1.904 + 0.403 9.747 + 2.164
16 1.47 + 0.03 2.105 + 0.482 10.512 + 2.329
17 1.46 + 0.03 2.108 + 0.428 10.705 + 2.277
18 1.40 + 0.05 2.104 + 0.439 10.005 + 1.827
19 1.52 + 0.01 2.121 + 0.497 10.984 + 2.243
20 1.44 + 0.05 1.940 + 0.376 9.452 + 1.844
21 1.47 + 0.04 2.080 + 0.440 10.450 + 2.382
22 1.44 + 0.04 2.115 + 0.566 10.295 + 2.881
23 1.47 + 0.04 1.845 + 0.407 3.976 + 1.957
24 1.50 +0.02 1.734 + 0.380 3.793 + 1.950
25 1.47 + 0.02 1.719 + 0.430 8.950 + 2.276
Table A. 2 - glucagon secretion in the two weeks
cold-exposed group. All values are expressed as the
mean + mean body weight = 308.0 + 6.1 g, n=8.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/ml)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.51 + 0.04 0.233 + 0.047 1 .306 + 0.255
2 1.48 + 0.04 0.179 + 0.021 0.987 + 0.131
3 1.45 + 0.04 0.200 + 0.029 1 .090 + 0.193
4 1.47 + 0.04 0.198 + 0.036 1 .092 + 0.234
5 1.40 + 0.05 0.203 + 0.041 1.111 + 0.288
6 1.38 + 0.05 0.203 + 1.168 40.765 + 7.781
7 1.45 + 0.05 2.173 + 0.417 1 1 .763 + 2.302
8 1.46 + 0.04 0.952 + 0.144 5.049 + 0.728
9 1.49 + 0.02 1.481 + 0.264 8.051 + 1.402
10 1.48 + 0.02 1 .834 + 0.249 9.683 + 1 048
11 1.48 + 0.02 1 .748 + 0.204 9.428 + 0.981
12 1.49 + 0.01 1.678 + 0.233 9.146 + 1.173
13 1.50 + 0.02 1.616 + 0.200 8.912 + 1.148
14 1 .44 + 0.05 1.878 + 0.284 10.244 + 2.026
15 1 .47 + 0.04 1.627 + 0.226 8.715 + 1.091
16 1.44 + 0.05 2.874 + 1.244 15.486 + 6.740
17 1.44 + 0.04 3.050 + 1.196 16.281 + 6.289
18 1 .48 + 0.02 1 .865 + 0.224 10.288 + 1.435
19 1.46 + 0.03 1.961 + 0.259 10.327 + 1.463
20 1.44 + 0.03 1 782 + 0.206 9.560 + 1.255
21 1.43 + 0.05 1.775 + 0.281 9.402 + 1.704
22 1.43 + 0.04 1.955 + 0.379 10.685 + 2.474
23 1.41 + 0.04 1.741 + 0.297 9.332 + 1.929
24 1.44 + 0.04 1.723 + 0.273 9.430 + 1.923
25 1.41 + 0.05 1.728 + 0.456 9.517 + 2.744
Table A.3 - glucagon secretion in the four weeks cold-exposed
group. All values are expressed as the Mean + S.E.M., mean
body weight = 306.0 +9.2 g, n=7.
SAMPLE VOLUME GLUCAGON GLUCAGON
TIME CONC. SECRETION RATE
(min) (mis) (ng/ml) (ng/min/g pane)
1 1.44 + 0.03 0.089 + 0.010 0.382 + 0.057
2 1.25 + 0.07 0.093 + 0.010 0.333 + 0.040
3 1.40 + 0.04 0.090 + 0.016 0.360 + 0.058
4 1.35 + 0.03 0.107 + 0.017 0.434 + 0.087
5 1.38 + 0.03 0.089 + 0.066 0.368 + 0.066
6 1.41 + 0.03 5.261 + 1.043 21.770 + 4.411
7 1.40 + 0.04 1.778 + 4.999 7.483 + 2.270
8 1.42 + 0.04 1.122 + 1.172 4.673 + 0.750
9 1.36 + 0.04 1.209 + 10.262 4.764 + 0.992
10 1.36 + 0.04 1.240 + 0.274 4.992 + 1.028
11 1.30 + 0.05 1.265 + 0.321 4.537 + 1.003
12 1.37 + 0.03 1.148 + 0.196 4.752 + 0.992
13 1.37 + 0.04 1.220 + 0.047 4.908 + 1.042
14 1.38 + 0.04 1.089 + 0.125 4.381 + 0.576
15 1.36 + 0.03 1.411 + 0.233 5.737 + 1.184
16 1.36 + 0.03 1.195 + 0.253 4.922 + 1.243
17 1.28 + 0.07 1.183 + 0.209 4.432 + 0.867
18 1.31 + 0.04 1.486 + 0.209 5.813 + 1.280
19 1.33 + 0.05 1.084 + 0.198 4.384 + 1.013
20 1 .34 hh 0.04 1.288 + 0.136 5.033 + 0.623
21 1.17 + 0.15 1.224 + 0.252 4.731 + 1 418
22 1.26 + 0.05 1.154 + 0.187 4.099 + 0.576
23 1.33 + 0.04 0.931 + 0.226 3.776 + 1.107
24 1.33 + 0.06 1.102 + 0.229 4.450 + 1.102
25 1.29 + 0.05 0.943 + 0.142 3.818 + 0.699
Table A.4 - glucagon secretion in the six weeks cold-exposed
group. All values are expressed as the Mean +_ S.E.M., mean
body weight = 348.0 +8.6 g, n=8.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/ml)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.48 + 0.13 0.170 + 0.064 0.762 + 0.225
2 1.46 + 0.13 0.187 + 0.050 0.805 . + 0.195
3 1.44 + 0.14 0.155 + 0.048 0.651 + 0.142
■4 1.43 + 0.16 0.130 + 0.036 0.567 + 0.120
5 1.44 + 0.17 0.149 + 0.042 0.648 + 0.154
6 1.34 + 0.08 4.045 + 0.808 17.572 + 3.095
7 1.34 + 0.05 16.673 + 0.726 7.094 + 2.811
8 1.30 + 0.06 0.987 + 0.294 4.060 + 0.923
9 1.43 + 0.05 1.126 + 0.249 5.280 + 1 .002
10 1.38 + 0.06 1 .510 + 0.278 6.917 + 1.075
11 1.31 + 0.05 1.425 + 0.268 6.225 + 1.037
12 1.33 + 0.05 1.142 + 0.195 5.076 + 0.756
13 1.31 + 0.05 1.382 + 0.262 6.149 + 1.137
14 1.32 + 0.05 1.418 + 0.253 5.731 + 0.949
15 1.37 + 0.05 1.356 + 0.222 6.299 + 1.160
16 1.18 + 0.11 1.469 + 0.419 6.148 + 1.989
17 1 .30 + 0.07 1.536 + 0.286 6.749 + 1.383
18 1.34 + 0.06 1.559 + 0.263 7.020 + 1.263
19 1.36 + 0.06 1.775 + 0.417 8.160 + 1.841
20 1.27 + 0.06 1.517 + 0.387 6.441 + 1.649
21 1.25 + 0.09 1.989 + 0.312 8.245 + 1.506
22 1.26 + 0.05 1.562 + 0.283 6.478 + 1.176
23 1.29 + 0.04 1 .434 + 0.267 6.265 + 1.258
24 1 .26 + 0.06 1.389 + 0.286 5.834 + 1.245
25 1.35 + 0.05 1 .304 + 0.417 5.980 + 1.885
Table A.5 - glucagon secretion in the 20 ng/100mls NA
warm group. All values are expressed as the Mean +_
S.E.M., mean body weiht = 328.0 +12.1 g, n=8.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/ml)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.47 + 0.002 0.103 + 0.007 0.595 + 0.065
2 1.34 + 0.12 0.123 + 0.023 0.729 + 0.175
3 1.46 + 0.03 0.119 + 0.020 0.697 + 0.154
4 1.45 + 0.03 0.116 + 0.020 0.649 + 0.115
5 1.42 + 0.04 0.126 + 0.024 0.638 + 0.142
6 1.46 + 0.02 6.188 + 0.865 35.468 + 6.195
7 1.52 +0.03 2.153 + 0.157 12.716 + 1.285
8 1.45 + 0.06 1.430 + 0.371 7.949 + 1.894
9 1.48 + 0.22 3.287 + 0.156 17.364 + 7.669
10 1.44 + 0.02 2.433 + 0.712 12.776 + 3.335
11 1.40 + 0.11 1.450 + 0.275 8.127 + 1.473
12 1.49 + 0.03 1 .437 + 0.367 8.002 + 1.964
13 1.51 + 0.02 1 .460 + 0.180 8.436 + 1.190
14 1.49 + 0.03 1.346 + 0.226 7.534 + 1.200
15 1.44 + 0.03 1.602 + 0.315 8.894 + 1.966
16 1.43 + 0.04 1 .754 + 0.269 9.542 + 1.615
17 1.47 + 0.02 2.094 + 0.419 12.069 + 2.749
18 1.46 + 0.02 1 .734 + 0.170 9.880 + 1.532
19 1.45 + 0.02 1 .591 + 0.298 8.679 + 1.622
20 1.38 + 0.04 1.525 + 0.213 8.500 + 1.602
21 1.39 + 0.06 1.437 + 0.094 8.000 + 1.010
22 1.48 + 0.03 1.730 + 0.135 9.961 + 1.585
23 1.38 +0.05 1.551 + 0.278 8.279 + 1.778
24 1.39 + 0.05 1.435 + 0.160 7.527 + 0.933
25 1.44 + 0.07 1.372 + 0.303 8.455 + 2.400
Table A.6 glucagon secretion in the 40 ng/100mls NA warm
group. All values are expressed as the Mean + S.E.M.,
mean body weight = 317.0 + 5.2 g, n=7.
SAMPLE VOLUME GLUCAGON GLUCAGON
TIME CONC. SECRETION RATE
(min) (mis) (ng/ml) (ng/min/g pane)
1 1.63 + 0.1.3 0.254 + 0.074 1 .443 + 0.432
2 1.69 + 0.12 0.242 + 0.059 1 .468 + 0.398
3 1.42 + 0.05 0.231 + 0.062 1.109 + 0.298
4 1.50 + 0.02 0.172 + 0.048 0.881 + 0.231
5 1.63 + 0.14 0.158 + 0.040 0.969 + 0.321
6 1.44 + 0.02 7.487 + 2.045 36.187 + 8.167
7 1.49 + 0.03 3.026 +0.312 14.779 + 3.516
8 1.47 + 0.02 2.702 + 1.149 12.954 + 4.757
9 1.47 + 0.03 2.923 + 1.091 13.979 + 4.565
10 1.47 + 0.02 3.418 + 1.240 15.553 + 4.374
11 1.47 + 0.03 2.744 + 0.882 13.059 + 3.561
12 1.45 + 0.03 2.268 + 0.818 10.720 + 3.215
13 1.46 + 0.02 2.020 + 0.607 9.798 + 2.564
14 1.44 + 0.03 1.991 + 0.693 9.334 + 2.995
15 1.40 + 0.05 2.205 + 0.830 10.510 + 3.632
16 1.40 + 0.03 2.461 + 0.664 11.433 + 2.626
17 1.42 + 0.05 2.443 + 0.685 11.720 + 3.127
18 1.47 + 0.05 2.338 + 0.725 11.295 + 2.985
19 1.45 + 0.03 1.929 + 0.519 9.505 + 2.254
20 1.44 + 0.01 2.375 + 0.528 1 1 .534 + 2.240
21 1.42 + 0.02 1.976 + 0.483 9.482 + 2.077
22 1.42 + 0.04 2.144 + 0.594 9.943 + 2.130
23 1.43 + 0.03 1.899 + 0.442 8.970 + 1.893
24 1.38 + 0.06 1.935 + 0.592 9.034 + 2.616
25 1.38 + 0.04 1.857 + 0.498 3.668 + 2.110
Table A.7 glucagon secreion in the 80 ng/100 rnls NA warm
group. All values are expressed as the Mean + S.E.M.,
mean body weight = 316.0+3.4 g, n=8.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/ml)
GLUCAGON 
SECRETION RATE 
(ng/inin/g pane)
1 1.59 + 0.13 0.178 +0.063 0.910 + 0.246
2 1.51 + 0.15 0.205 + 0.074 0.970 + 0.287
3 1.54 + 0.12 0.208 + 0.086 1 .170 + 0.526
4 1.45 + 0.02 0.194 + 0.085 0.866 + 0.304
5 1.42 + 0.04 0.177 + 0.064 0.705 + 0.103
6 1.40 + 0.03 10.949 + 1.999 51.099 + 7.576
7 1.50 + 0.03 3.385 +0.524 16.815 + 2.197
8 1.52 + 0.03 1.099 + 0.201 5.548 + 0.830
9 1.53 + 0.03 1.979 + 0.379 9.795 + 1.426
10 1 .54 + 0.03 2.815 + 0.567 14.002 + 2.286
11 1.53 + 0.02 2.678 + 0.543 13.393 + 1.824
12 1.48 + 0.03 2.378 +0.473 11 .707 + 1 .813
13 1.49 + 0.04 2.229 + 0.513 11 .008 + 2.100
14 1.46 + 0.06 2.094 + 0.471 16.019 + 1.784
15 1.49 + 0.03 2.303 +0.667 10.952 + 2.400
16 1.47 + 0.02 2.348 + 0.627 11 .087 + 2.174
17 1.53 + 0.02 3.176 + 0.899 15.644 + 3.692
18 1.47 + 0.06 3.063 + 0.793 14.518 + 2.831
19 1.50 + 0.04 2.877 + 0.892 13.650 + 3.129
20 1.52 + 0.02 2.573 + 0.694 12.735 + 2.746
21 1.51 + 0.03 2.409 + 0.837 11.595 + 3.069
22 1.50 + 0.03 1.931 + 0.521 9.207 + 2.405
23 1.50 + 0.04 1.869 + 0.359 9.222 + 1.222
24 1.48 + 0.04 2.177 + 0.695 10.358 + 2.596
25 1.54 + 0.04 2.004 + 0.777 9.540 + 2.878
Table A.8 glucagon secretion in the 100 ng/100mls NA
warm group. All values are expressed as the Mean +
S.E.M., mean body weight = 307.0 + 12.6 g, n=8.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/ml)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.54 + 0.04 0.150 +0.028 0.752 + 0.155
2 1.54 + 0.02 0.121 + 0.024 0.619 + 0.136
3 1.36 + 0.08 0.273 + 0.127 1.256 + 0.603
4 1.40 + 0.07 0.280 + 0.159 1.354 + 0.738
5 1.41 + 0.07 0.127 + 0.029 0.624 + 0.163
6 1.34 + 0.05 6.016 + 0.117 26.359 + 5.604
7 1.49 + 0.02 2.535 + 0.434 12.689 + 2.616
8 1.49 + 0.03 1.381 + 0.216 6.994 + 1.323
9 1.52 + 0.03 1.540 + 0.257 7.886 + 1.457
10 1.54 + 0.03 1.812 + 0.292 9.326 + 1.628
11 1.51 + 0.03 1.814 + 0.404 9.401 + 2.231
12 1.50 + 0.03 2.004 + 0.331 .10.129 + 1.860
13 1.47 + 0.03 1.881 + 0.397 9.628 + 2.244
14 1.51 + 0.03 2.271 + 0.412 11 .581 + 2.354
15 1 .47 + 0.03 2.152 + 0.409 10.811 + 2.237
16 1.46 + 0.02 2.189 + 0.352 10.802 + 1.956
17 1.48 + 0.03 2.172 + 0.364 10.940 + 2.058
18 1.47 + 0.03 2.246 + 0.467 11 .195 + 2.525
19 1.49 + 0.03 1.004 + 0.377 10.026 + 1.945
20 1.50 + 0.04 2.253 + 0.394 11.606 + 2.294
21 1.48 + 0.03 2.061 + 0.428 10.131 + 2.273
22 1.47 + 0.03 2.138 + 0.382 10.596 + 2.048
23 1.50 + 0.03 1.919 + 0.377 9.880 + 2.204
24 1 .47 + 0.04 1.915 + 0.263 9.979 + 1.760
25 1.48 + 0.03 1.610 + 0.258 8.392 + 1.586
Table A.9 - Glucagon secretion in the 20 ng/100mls NA
cold group. All values are expressed as the Mean +
S.E.M., mean body weights = 327.0 + 7.2 g, N=8.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/ml)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.49 + 0.02 0.180 + 0.044 0.820 + 0.251
2 1.57 + 0.02 0.166 + 0.039 0.795 + 0.237
3 1.62 + 0.01 0.178 + 0.035 0.861 + 0.226
4 1.46 + 0.03 0.202 + 0.059 0.784 + 0.221
5 1.51 ± 0.04 0.191 + 4.076 0.863 + 3.386
6 1.37 +0.05 9.703 + 1.064 36.147 + 4.813
7 • 1.52 + 0.04 4.228 +0.729 17.165 + 0.307
8 1.50 + 0.04 2.068 + 0.568 9.045 + 3.249
9 1.54 + 0.03 2.764 + 0.752 12.572 + 4.460
10 1.53 + 0.03 3.000 + 0.620 13.004 + 3.612
11 1.50 +0.04 2.964 + 0.697 12.773 + 3.897
12 1.52 + 0.05 2.720 + 0.495 11.582 + 2.709
13 1.49 + 0.04 2.838 + 0.650 1 1.704 + 3.264
14 1.50 + 0.05 2.842 + 0.535 11.818 + 2.655
15 1.47 + 0.05 2.769 + 0.530 11.353 + 2.825
16 1.52 + 0.04 2.712 + 0.448 11.714 + 2.834
17 1.53 + 0.04 2.811 + 0.353 12.470 + 2.537
18 1.47 +0.04 3.036 + 0.578 12.988 + 3.683
19 1.50 + 0.04 2.779 + 0.480 11 .591 + 2.535
20 1.48 + 0.04 3.090 + 0.724 13.131 + 3.992
21 1.50 + 0.04 2.671 + 0.610 11.445 + 3.442
22 1.50 + 0.04 2.569 + 0.372 10.644 + 2.058
23 1.50 + 0.03 2.412 + 0.489 10.207 + 2.773
24 1.46 + 0.03 2.720 + 0.595 11.467 + 3.473
25 1.50 + 0.02 2.860 + 0.683 12.151 + 3.721
Table A.10 - Glucagon secretion in the 40 ng/100 mis NA
cold group. All values are expressed as the Mean +
S.E.M., mean body weight = 350.0 + 6.0 g, n=9.
SAMPLE VOLUME GLUCAGON GLUCAGON
TIME CONC. SECRETION RATE
(min) (mis) (ng/ml) (ng/min/g pane)
1 1.43 + 0.14 0.130 + 0.018 0.592 + 0.089
2 1.55 + 0.08 0.143 + 0.016 0.742 + 0.082
3 1.55 + 0.01 0.135 + 0.016 0.708 + 0.092
4 1.71 + 0.17 0.132 + 0.008 0.773 + 0.123
5 1.48 + 0.04 0.120 + 0.012 0.598 + 0.064
6 1.24 + 0.13 11 .483 + 1 .915 50.144 +10.444
7 1.47 + 0.03 2.299 + 0.328 11.376 + 1.564
8 1.52 + 0.03 1.180 + 0.071 5.997 + 0.355
9 1.49 + 0.03 2.238 + 0.381 11.166 + 1.931
10 1.49 + 0.02 2.267 + 0.237 11.360 + 1.235
11 1.47 + 0.03 2.877 + 0.215 14.250 + 1.268
12 1.47 + 0.03 2.632 + 0.257 13.272 + 1.356
13 1.45 + 0.03 2.505 + 0.196 12.246 + 1.057
14 1.45 + 0.05 2.722 + 0.269 13.210 + 1.280
15 1.45 + 0.03 2.718 + 0.295 13.259 + 1.483
16 1.45 + 0.03 2.996 + 0.536 14.402 + 2.295
17 1.54 + 0.03 2.986 + 0.445 15.356 + 2.151
18 1.51 + 0.02 2.859 + 0.331 14.839 + 1.601
19 1.52 + 0.02 6.458 + 4.283 31.009 +19.738
20 1.51 + 0.01 2.755 + 0.317 14.022 + 1.616
21 1.50 + 0.02 2.408 + 0.239 12.113 + 1.189
22 1.52 + 0.03 1.819 + 0.301 9.404 + 1.585
23 1.48 + 0.02 2.163 + 0.369 10.809 + 0.870
24 1.47 + 0.02 2.3893,+ 0*170 11.811 + 0.895
25 1.49 + 0.02 2.394 + 0.314 12.113 + 1.942
Table A.11 - Glucagon secretion in the 80 ng/100mls cold
group. All values are expressed as the Mean + S.E.M.,
mean body weight = 328.0 +6.2 g, n=7.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/rnl)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.39 + 0.05 0.166 + 0.032 0.837 + 0.148
2 1.43 + 0.08 0.179 + 0.023 0.880 + 0.107
3 1.46 + 0.07 0.178 + 0.025 0.913 + 0.086
4 1.51 + 0.04 0.172 + 0.018 0.848 + 0.075
5 1.46 + 0.06 0.187 + 0.021 0.879 + 0.080
6 1.37 + 0.06 10.762 + 1.623 44.016 + 7.372
7 1.53 + 0.03 2.670 + 0.465 15.552 + 2.555
8 1.51 + 0.04 1 .734 + 0.272 9.624 + 1.474
9 1.47 + 0.04 2.312 + 0.281 12.741 + 1.625
10 1,52 + 0.03 2.513 + 0.311 13.195 + 1.493
11 1.49 + 0.04 2.628 + 0.230 15.440 + 2.246
12 1 .49 + 0.03 2.708 + 0.323 15.193 + 2.018
13 1.51 + 0.03 2.848 + 0.502 15.322 + 2.155
14 1.51 + 0.02 2.510 + 0.287 14.250 + 2.216
15 1.54 + 0.03 2.509 + 0.367 14.902 + 2.462
16 1.56 + 0.03 2.389 + 0.354 13.682 + 2.036
17 1.52 + 0.03 2.856 + 0.504 16.400 + 2.696
18 1.52 + 0.03 2.350 + 0.229 13.818 + 2.035
19 1.45 + 0.11 2.405 + 0.313 14.955 + 2.919
20 1.49 + 0.04 2.326 + 0.299 14.434 + 2.510
21 1.53 + 0.03 2.542 + 0.447 14.873 + 2.493
22 1.50 + 0.04 3.128 + 0.283 16.730 + 1.924
23 1.25 + 0.15 2.630 + 0.554 10.994 + 1.683
24 1.40 + 0.11 2.334 + 0.308 13.542 + 2.505
25 1.48 + 0.03 2.473 + 0.517 12.398 + 2.306
Table A. 12 - Glucagon secretion in the 100 ng/100mls NA
cold group. All values are expressed as the Mean +_
S.E.M., mean body weights = 337.0 + 9.9 g, n=7.
SAMPLE VOLUME GLUCAGON GLUCAGON
TIME CONC. SECRETION RATE
(min) (mis) (ng/ml) (ng/min/g pane)
1 1.35 + 0.05 0.337 + 0.077 2.345 + 0.629
2 1.28 + 0.04 0.339 + 0.089 2.399 + 0.825
3 1.29 + 0.05 0.335 + 0.080 2.338 + 0.716
4 1.22 + 0.09 0.318 + 0.066 2.095 + 0.645
5 1.22 + 0.07 0.339 + 0.082 2.219 + 0.628
6 1.36 + 0.08 7.970 + 0.887 57.746 +10.984
7 1.37 + 0.04 1 .742 + 0.200 11.170 + 1.166
8 1.35 + 0.04 0.690+0.107 4.838 + 0.894
9 1.36 + 0.05 1 .478 + 0.408 9.959 + 3.128
10 1 .38 + 0.05 1.281 + 0.260 8.513 + 1.452
11 1.38 + 0.05 1 .347 + 0.232 8.961 + 1.342
12 1.36 + 0.06 1.286 + 0.186 8.402 + 1.034
13 1.35 + 0.03 1.420 + 0.020 9.405 + 1.413
14 1.33 + 0.05 1 .534 + 0.170 9.960 + 1.077
15 1.32 + 0.06 1.507 + 0.148 9.638 + 0.900
16 1.33 ± 0.06 1.492 + 0.187 10.419 + 1.817
17 1.33 + 0.05 1.513 + 0.296 9.907 + 2.059
18 1.29 + 0.06 1.758 + 0.255 10.958 + 1.599
19 1.31 + 0.07 2.092 + 0.322 13.044 + 1.709
20 1.35 + 0.07 1.619 + 0.218 10.827 + 1.697
21 1.29 + 0.05 1.597 + 0.850 10.087 + 2.754
22 1.29 + 0.09 1 .637 + 0.164 10.338 + 1.339
23 1.23 + 0.07 1 .791 + 0.224 11.693 + 1.829
24 1.25 + 0.08 1.805 + 0.333 11 .708 + 2.144
25 1.25 + 0.08 2.048 + 0.292 11.812 + 2.258
Table A.13 - Glucagon secretion in the warm
phentolamine-treated group. All values are expressed as
the Mean + S.E.M., mean body weight 305.0 + 6.8 g, n=7.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/inl)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.34 + 0.06 0.121 +0.024 0.651 + 0.154
2 1.37 + 0.03 0.124 + 0.023 0.704 +0.165
3 1.34 + 0.03 0.116+ 0.020 0.623 + 0.122
4 1.36 + 0.03 0.125 + 0.020 0.708 + 0.162
5 1.36 + 0.04 0.102 + 0.018 0.554 + 0.108
6 1.38 + 0.02 1 .313 + 0.352 6.788 + 1.507
7 1.40 + 0.03 0.382 + 0.029 2.199 +0.249
8 1.38 + 0.02 0.387 + 0.021 2.132 + 0.226
9 1.37 + 0.02 0.504 + 0.072 2.844 + 0.637
10 1.30 + 0.02 0.553 + 0.065 2.795 + 0.306
11 1.35 + 0.02 0.507 + 0.072 2.654 + 0.358
12 1.35 + 0.02 0.497 + 0.066 2.614 + 0.318
13 1.35 + 0.02 0.429 + 0.045 2.259 + 0.234
14 1.29 + 0.02 0.629 + 0.135 3.208 + 0.753
15 1.35 + 0.02 0.422 + 0.055 2.223 + 0.300
16 1.35 + 0.02 0.523 + 0.069 2.734+0.349
17 1.28 + 0.04 0.494 + 0.063 2.579 + 0.474
18 1.34 + 0.02 0.499 + 0.072 2.606 + 0.365
19 1.31 + 0.03 0.443 + 0.063 2.406 + 0.572
20 1.31 + 0.03 0.531 + 0.094 2.746 + 0.520
21 1.26 + 0.05 0.433 + 0.057 2.153 + 0.523
22 1 .28 + 0.04 0.450 + 0.055 2.349 + 0.372
23 1 .26 + 0.04 0.533 + 0.082 2.609 + 0.390
24 1 .27 + 0.02 0.385 + 0.048 1.948 + 0.280
25 1.27 + 0.04 0.406 + 0.067 1.812 + 0.257
Table A.14 - Glucagon secretion in the warm
propranolol-treated group. All values are expressed as 
the Mean + S.E.M., mean body weights = 318.0 + 7.4 g,
n=7.
SAMPLE VOLUME GLUCAGON GLUCAGON
TIME CONC. SECRETION RATE
(min) (mis.) (ng/ml) (ng/min/g pane)
1 1.19 + 0.13 0.078 + 0.012 0.295 + 0.063
2 1.27 + 0.04 0.088 + 0.018 0.351 + 0.072
3 1.25 + 0.06 0.086 + 0.010 0.307 + 0.036
4 1.22 + 0.01 0.065 + 0.005 0.244 + 0.030
5 1.31 + 0.07 0.062 + 0.004 0.257 + 0.028
6 1.19 + 0.14 1.332 + 0.439 5.696 +- 2.709
7 1.30 + 0.02 0.786 + 0.212 3.173 + 0.824
8 1.21 + 0.07 0.683 + 0.210 2.371 + 0.538
9 1.19 + 0.17 0.685 + 0.198 2.882 + 1.139
10 1.23 + 0.09 0.880 + 0.407 3.270 + 1.465
11 1 .22 + 0.10 0.604 + 0.106 2.400 + 0.527
12 1.32 + 0.04 0.885 + 0.254 3.765 + 1.103
13 1.31 + 0.04 0.538 + 0.103 2.194 + 0.412
14 1.35 + 0.05 0.744 + 0.165 3.240 + 0.782
15 1.38 + 0.05 0.758 + 0.171 3.237 + 0.684
16 1.32 + 0.06 0.652 + 0.134 2.829 + 0.677
17 1.25 + 0.07 0.570 + 0.098 2.254 + 0.450
18 1.32 + 0.05 0.597 + 0.121 2.399 + 0.452
19 1.32 + 0.05 0.587 + 0.108 2.498 + 0.537
20 1.34 + 0.06 0.534 + 0.086 2.292 + 0.404
21 1.29 + 0.07 0.467 + 0.094 1.905 + 0.426
22 1.13 + 0.18 0.494 + 0.070 1.907 + 0.434
23 1.21 + 0.06 0.688 + 0.165 2.478 + 0.486
24 1.28 + 0.07 0.497 + 0.088 1.894 + 0.336
25 1 .22 + 0.08 0.376 + 0.045 1.510 + 0.273
Table A.15 - Glucagon secretion in the cold
phentolamine-treated group. All values are expressed as
the Mean + S.E.M., mean body weight = 3-41.0 + 9.6 g,
n=7.
SAMPLE
TIME
(min)
VOLUME
(mis)
GLUCAGON
CONC.
(ng/ml)
GLUCAGON 
SECRETION RATE 
(ng/min/g pane)
1 1.28 + 0.10 0.119 + 0.018 0.417 + 0.045
2 1.37 + 0.03 0.106 + 0.018 0.420 + 0.070
3 1.34 + 0.06 0.117 + 0.019 0.456 + 0.078
4 1.29 + 0.04 0.116 + 0.021 0.436 + 0.091
5 1.28 + 0.07 0.100 + 0.019 0.363 + 0.058
6 1.28 + 0.03 4.293 + 0.876 15.824 + 3.662
7 1.25 + 0.07 1 .075 + 0.385 3.510 + 1.164
8 1.28 + 0.08 0.820 + 0.239 3.016 + 0.831
9 1.32 + 0.05 1.140 + 0.317 4.345 + 1.002
10 1.34 + 0.05 1.080 + 0.259 4.136 + 0.892
11 1.32 + 0.06 1.196 + 0.324 4.486 + 1.110
12 1.25 + 0.09 1.238 + 0.393 4.265 + 1.266
13 1.30 + 0.07 1 .166 + 0.356 4.100 + 1.076
14 1.30 + 0.07 0.924 + 0.249 3.295 + 0.746
15 1.27 + 0.05 0.989 + 0.239 3.711 + 0.932
16 1.29 + 0.05 1.086 + 0.225 3.989 + 0.702
17 1.28 + 0.07 1.080 + 0.359 3.659 + 0.968
18 1.26 + 0.04 1.034 + 0.253 3.652 + 0.780
19 1.24 + 0.07 1.202 + 0.394 3.911 + 0.803
20 1.24 + 0.07 1.260+ 0.342 4.220 + 0.985
21 1.23 + 0.08 0.744 + 0.239 2.414 + 0.642
22 1.25 ± 0.07 1.380 + 0.048 4.854 + 1.763
23 1.18 + 0.08 1.360 + 0.472 4.170 + 1.526
24 1.19 + 0.07 1.615 + 0.419 3.281 + 1.382
25 1 .22 + 0.09 0.746 + 0.420 2.639 + 1.427
Table A.16 - Glucagon secretion in the cold
propranolol-treated group. All values are expressed as 
the Mean + S.E.M., mean body weight = 336.0 + 8.2 g,
n=7.
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